Journal Article
. 2015 Jun; 373(1):23-34.
doi: 10.1056/NEJMoa1504030.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

James Larkin 1 Vanna Chiarion-Sileni  Rene Gonzalez  Jean Jacques Grob  C Lance Cowey  Christopher D Lao  Dirk Schadendorf  Reinhard Dummer  Michael Smylie  Piotr Rutkowski  Pier F Ferrucci  Andrew Hill  John Wagstaff  Matteo S Carlino  John B Haanen  Michele Maio  Ivan Marquez-Rodas  Grant A McArthur  Paolo A Ascierto  Georgina V Long  Margaret K Callahan  Michael A Postow  Kenneth Grossmann  Mario Sznol  Brigitte Dreno  Lars Bastholt  Arvin Yang  Linda M Rollin  Christine Horak  F Stephen Hodi  Jedd D Wolchok  
  • PMID: 26027431
  •     16 References
  •     2683 citations


Background: Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4] checkpoint inhibitor) have been shown to have complementary activity in metastatic melanoma. In this randomized, double-blind, phase 3 study, nivolumab alone or nivolumab plus ipilimumab was compared with ipilimumab alone in patients with metastatic melanoma.

Methods: We assigned, in a 1:1:1 ratio, 945 previously untreated patients with unresectable stage III or IV melanoma to nivolumab alone, nivolumab plus ipilimumab, or ipilimumab alone. Progression-free survival and overall survival were coprimary end points. Results regarding progression-free survival are presented here.

Results: The median progression-free survival was 11.5 months (95% confidence interval [CI], 8.9 to 16.7) with nivolumab plus ipilimumab, as compared with 2.9 months (95% CI, 2.8 to 3.4) with ipilimumab (hazard ratio for death or disease progression, 0.42; 99.5% CI, 0.31 to 0.57; P<0.001), and 6.9 months (95% CI, 4.3 to 9.5) with nivolumab (hazard ratio for the comparison with ipilimumab, 0.57; 99.5% CI, 0.43 to 0.76; P<0.001). In patients with tumors positive for the PD-1 ligand (PD-L1), the median progression-free survival was 14.0 months in the nivolumab-plus-ipilimumab group and in the nivolumab group, but in patients with PD-L1-negative tumors, progression-free survival was longer with the combination therapy than with nivolumab alone (11.2 months [95% CI, 8.0 to not reached] vs. 5.3 months [95% CI, 2.8 to 7.1]). Treatment-related adverse events of grade 3 or 4 occurred in 16.3% of the patients in the nivolumab group, 55.0% of those in the nivolumab-plus-ipilimumab group, and 27.3% of those in the ipilimumab group.

Conclusions: Among previously untreated patients with metastatic melanoma, nivolumab alone or combined with ipilimumab resulted in significantly longer progression-free survival than ipilimumab alone. In patients with PD-L1-negative tumors, the combination of PD-1 and CTLA-4 blockade was more effective than either agent alone. (Funded by Bristol-Myers Squibb; CheckMate 067 number, NCT01844505.).

Improved overall survival in melanoma with combined dabrafenib and trametinib.
Caroline Robert, Boguslawa Karaszewska, +24 authors, Dirk Schadendorf.
N Engl J Med, 2014 Nov 18; 372(1). PMID: 25399551
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors.
Michael A Curran, Welby Montalvo, Hideo Yagita, James P Allison.
Proc Natl Acad Sci U S A, 2010 Feb 18; 107(9). PMID: 20160101    Free PMC article.
Highly Cited.
Pathways and therapeutic targets in melanoma.
Emma Shtivelman, Michael Q A Davies, +5 authors, David E Fisher.
Oncotarget, 2014 Apr 20; 5(7). PMID: 24743024    Free PMC article.
Highly Cited. Review.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
Georgina V Long, Daniil Stroyakovskiy, +32 authors, Keith Flaherty.
N Engl J Med, 2014 Sep 30; 371(20). PMID: 25265492
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
Improved survival with ipilimumab in patients with metastatic melanoma.
F Stephen Hodi, Steven J O'Day, +26 authors, Walter J Urba.
N Engl J Med, 2010 Jun 08; 363(8). PMID: 20525992    Free PMC article.
Highly Cited.
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
Omid Hamid, Caroline Robert, +23 authors, Antoni Ribas.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724846    Free PMC article.
Highly Cited.
Nivolumab in previously untreated melanoma without BRAF mutation.
Caroline Robert, Georgina V Long, +25 authors, Paolo A Ascierto.
N Engl J Med, 2014 Nov 18; 372(4). PMID: 25399552
Highly Cited.
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
Caroline Robert, Luc Thomas, +21 authors, Jedd D Wolchok.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639810
Highly Cited.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, +26 authors, BRIM-3 Study Group.
N Engl J Med, 2011 Jun 07; 364(26). PMID: 21639808    Free PMC article.
Highly Cited.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber, Sandra P D'Angelo, +25 authors, James Larkin.
Lancet Oncol, 2015 Mar 22; 16(4). PMID: 25795410
Highly Cited.
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
Michele Maio, Jean-Jacques Grob, +9 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 26; 33(10). PMID: 25713437    Free PMC article.
Highly Cited.
Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
James Larkin, Paolo A Ascierto, +16 authors, Antoni Ribas.
N Engl J Med, 2014 Sep 30; 371(20). PMID: 25265494
Highly Cited.
Melanoma: CheckMate 067--frontline nivolumab improves PFS alone or in combination with ipilimumab.
Alessia Errico.
Nat Rev Clin Oncol, 2015 Jun 24; 12(8). PMID: 26099982
Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma?
Axel Hauschild, Claus Garbe.
Nat Rev Clin Oncol, 2015 Jun 24; 12(8). PMID: 26099985
What's new in melanoma? Combination!
Paolo A Ascierto, Francesco M Marincola, Michael B Atkins.
J Transl Med, 2015 Jul 05; 13. PMID: 26141621    Free PMC article.
CIMT 2015: The right patient for the right therapy - Report on the 13th annual meeting of the Association for Cancer Immunotherapy.
Lena M Kranz, Matthias Birtel, +8 authors, Mustafa Diken.
Hum Vaccin Immunother, 2015 Jul 18; 12(1). PMID: 26186022    Free PMC article.
Nivolumab: A Review in Advanced Melanoma.
Lesley J Scott.
Drugs, 2015 Jul 30; 75(12). PMID: 26220912
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.
Jingjing Wu, Jiaping Fu, Mingzhi Zhang, Delong Liu.
J Hematol Oncol, 2015 Aug 02; 8. PMID: 26231785    Free PMC article.
Targeted drug combinations: avant-garde oncology.
Tu D Dan, Joshua D Palmer.
Ann Transl Med, 2015 Aug 06; 3(11). PMID: 26244146    Free PMC article.
Prospects of immune checkpoint modulators in the treatment of glioblastoma.
Matthias Preusser, Michael Lim, +2 authors, John H Sampson.
Nat Rev Neurol, 2015 Aug 12; 11(9). PMID: 26260659    Free PMC article.
Highly Cited. Review.
Adaptive Immune Resistance: How Cancer Protects from Immune Attack.
Antoni Ribas.
Cancer Discov, 2015 Aug 15; 5(9). PMID: 26272491    Free PMC article.
Highly Cited. Review.
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Ruea-Yea Huang, Cheryl Eppolito, +3 authors, Kunle Odunsi.
Oncotarget, 2015 Sep 01; 6(29). PMID: 26318293    Free PMC article.
Highly Cited.
[Immunotherapy of head and neck tumors: Highlights of the ASCO Meeting 2015].
S Laban, J Doescher, +4 authors, T K Hoffmann.
HNO, 2015 Sep 01; 63(9). PMID: 26319429
Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators.
Isabelle Le Mercier, J Louise Lines, Randolph J Noelle.
Front Immunol, 2015 Sep 09; 6. PMID: 26347741    Free PMC article.
Highly Cited. Review.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Repeated stereotactic radiosurgery for patients with progressive brain metastases.
Giuseppe Minniti, Claudia Scaringi, +6 authors, Riccardo Maurizi Enrici.
J Neurooncol, 2015 Sep 16; 126(1). PMID: 26369769
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
J Naidoo, D B Page, +5 authors, J D Wolchok.
Ann Oncol, 2015 Sep 16; 26(12). PMID: 26371282    Free PMC article.
Highly Cited. Review.
The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.
Lijo John, C Lance Cowey.
Dermatol Ther (Heidelb), 2015 Sep 21; 5(3). PMID: 26387031    Free PMC article.
Nivolumab in combination with ipilimumab for the treatment of melanoma.
Rajasekharan Somasundaram, Meenhard Herlyn.
Expert Rev Anticancer Ther, 2015 Sep 25; 15(10). PMID: 26402246    Free PMC article.
Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.
N Yamazaki, Y Kiyohara, +8 authors, T Tokudome.
Cancer Chemother Pharmacol, 2015 Sep 28; 76(5). PMID: 26410424    Free PMC article.
TIGIT predominantly regulates the immune response via regulatory T cells.
Sema Kurtulus, Kaori Sakuishi, +6 authors, Ana C Anderson.
J Clin Invest, 2015 Sep 29; 125(11). PMID: 26413872    Free PMC article.
Highly Cited.
Biomodulatory metronomic therapy in stage IV melanoma is well-tolerated and may induce prolonged progression-free survival, a phase I trial.
C Hart, M Vogelhuber, +5 authors, A Reichle.
J Eur Acad Dermatol Venereol, 2016 Oct 25; 30(11). PMID: 26417987    Free PMC article.
Immunotherapy in Sarcoma: Future Horizons.
Melissa Burgess, Vikram Gorantla, Kurt Weiss, Hussein Tawbi.
Curr Oncol Rep, 2015 Oct 02; 17(11). PMID: 26423769
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.
Stuart J Gallagher, Jessamy C Tiffen, Peter Hersey.
Cancers (Basel), 2015 Oct 02; 7(4). PMID: 26426052    Free PMC article.
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies.
Yi Xia, L Jeffrey Medeiros, Ken H Young.
Biochim Biophys Acta, 2015 Oct 04; 1865(1). PMID: 26432723    Free PMC article.
Comprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice.
Luís Felipe Campesato, Romualdo Barroso-Sousa, +6 authors, Anamaria A Camargo.
Oncotarget, 2015 Oct 07; 6(33). PMID: 26439694    Free PMC article.
Highly Cited.
Editorial: Advances in Combination Tumor Immunotherapy.
Michael A Curran, Bernard A Fox, William L Redmond.
Front Oncol, 2015 Oct 07; 5. PMID: 26442210    Free PMC article.
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data.
Patrick A Ott, F Stephen Hodi, Elizabeth I Buchbinder.
Front Oncol, 2015 Oct 07; 5. PMID: 26442214    Free PMC article.
Highly Cited. Review.
Resection Followed by Involved-Field Fractionated Radiotherapy in the Management of Single Brain Metastasis.
Samuel M Shin, Ralph E Vatner, +4 authors, Joshua Seth Silverman.
Front Oncol, 2015 Oct 07; 5. PMID: 26442218    Free PMC article.
Novel Therapies for Metastatic Melanoma: An Update on Their Use in Older Patients.
Aljosja Rogiers, Joost J van den Oord, +5 authors, Pascal Wolter.
Drugs Aging, 2015 Oct 08; 32(10). PMID: 26442859
Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes.
Morganna Freeman-Keller, Youngchul Kim, +3 authors, Jeffrey S Weber.
Clin Cancer Res, 2015 Oct 09; 22(4). PMID: 26446948    Free PMC article.
Highly Cited.
Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.
Jacob Hurst, Matthias Hoffmann, +19 authors, John Frater.
Nat Commun, 2015 Oct 10; 6. PMID: 26449164    Free PMC article.
Highly Cited.
The Immunotherapy Roadmap.
James C Yang.
Clin Cancer Res, 2015 Oct 16; 22(2). PMID: 26459176    Free PMC article.
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Jennifer Kleponis, Richard Skelton, Lei Zheng.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487965    Free PMC article.
Advances in immunotherapy for treatment of lung cancer.
Jean G Bustamante Alvarez, María González-Cao, +4 authors, Rafael Rosell.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487966    Free PMC article.
Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?
Matthias Preusser, Anna S Berghoff, Wolfgang Wick, Michael Weller.
Clin Neuropathol, 2015 Oct 27; 34(6). PMID: 26501438    Free PMC article.
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Sherene Loi, Sathana Dushyanthen, +22 authors, Justin M Balko.
Clin Cancer Res, 2015 Oct 31; 22(6). PMID: 26515496    Free PMC article.
Highly Cited.
Immunomodulation: checkpoint blockade etc.
William T Curry, Michael Lim.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516223    Free PMC article.
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Katy K Tsai, Adil I Daud.
J Hematol Oncol, 2015 Nov 01; 8. PMID: 26518223    Free PMC article.
Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
Lijie Zhai, Stefani Spranger, +4 authors, Derek A Wainwright.
Clin Cancer Res, 2015 Nov 01; 21(24). PMID: 26519060    Free PMC article.
Highly Cited. Review.
Novel immunotherapies in lymphoid malignancies.
Connie Lee Batlevi, Eri Matsuki, Renier J Brentjens, Anas Younes.
Nat Rev Clin Oncol, 2015 Nov 04; 13(1). PMID: 26525683    Free PMC article.
Highly Cited. Review.
Clinical Relevance of Androgen Receptor Splice Variants in Castration-Resistant Prostate Cancer.
Benjamin L Maughan, Emmanuel S Antonarakis.
Curr Treat Options Oncol, 2015 Nov 06; 16(12). PMID: 26537882
Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Lisa Zimmer, Thomas K Eigentler, +15 authors, Dirk Schadendorf.
J Transl Med, 2015 Nov 07; 13. PMID: 26541511    Free PMC article.
The Wnts of change: How Wnts regulate phenotype switching in melanoma.
Marie R Webster, Curtis H Kugel, Ashani T Weeraratna.
Biochim Biophys Acta, 2015 Nov 08; 1856(2). PMID: 26546268    Free PMC article.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Stemming the Rising Incidence of Melanoma: Calling Prevention to Action.
Jeffrey E Gershenwald, Gery P Guy.
J Natl Cancer Inst, 2015 Nov 14; 108(1). PMID: 26563358    Free PMC article.
A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.
George R Nahas, Nykia D Walker, Margarette Bryan, Pranela Rameshwar.
Breast Cancer (Auckl), 2015 Nov 17; 9(Suppl 2). PMID: 26568682    Free PMC article.
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Ivan Márquez-Rodas, Pablo Cerezuela, +4 authors, Salvador Martín-Algarra.
Ann Transl Med, 2015 Nov 26; 3(18). PMID: 26605313    Free PMC article.
European Cancer Congress 2015.
Walter Alexander.
P T, 2015 Nov 27; 40(11). PMID: 26609211    Free PMC article.
Immune suppressive mechanisms in the tumor microenvironment.
David H Munn, Vincenzo Bronte.
Curr Opin Immunol, 2015 Nov 27; 39. PMID: 26609943    Free PMC article.
Highly Cited. Review.
IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.
Karolina Pilipow, Alessandra Roberto, +3 authors, Enrico Lugli.
Cancer Res, 2015 Dec 03; 75(24). PMID: 26627006    Free PMC article.
Investigation of FOXM1 as a Potential New Target for Melanoma.
Azusa Miyashita, Satoshi Fukushima, +7 authors, Hironobu Ihn.
PLoS One, 2015 Dec 08; 10(12). PMID: 26640950    Free PMC article.
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, +41 authors, Patrick Hwu.
Cancer Discov, 2015 Dec 10; 6(2). PMID: 26645196    Free PMC article.
Highly Cited.
Clinical relevance of host immunity in breast cancer: from TILs to the clinic.
Peter Savas, Roberto Salgado, +4 authors, Sherene Loi.
Nat Rev Clin Oncol, 2015 Dec 17; 13(4). PMID: 26667975
Highly Cited. Review.
Immunotherapy in Tumors.
Sebastian Kobold, Peter Duewell, +3 authors, Stefan Endres.
Dtsch Arztebl Int, 2015 Dec 17; 112(48). PMID: 26667979    Free PMC article.
Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations.
Michael P Castro, Neal Goldstein.
J Immunother Cancer, 2015 Dec 18; 3. PMID: 26674132    Free PMC article.
Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies.
Noura Choudhury, Yusuke Nakamura.
Cancer Sci, 2015 Dec 19; 107(2). PMID: 26678880    Free PMC article.
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.
Ali Ghasemzadeh, Trinity J Bivalacqua, Noah M Hahn, Charles G Drake.
Clin Cancer Res, 2015 Dec 20; 22(4). PMID: 26683632    Free PMC article.
Cancer immunotherapy: A vaccine from plant virus proteins.
Pier Paolo Peruzzi, E Antonio Chiocca.
Nat Nanotechnol, 2015 Dec 23; 11(3). PMID: 26689377
Current progress in immunotherapy for pancreatic cancer.
Kelly Foley, Victoria Kim, Elizabeth Jaffee, Lei Zheng.
Cancer Lett, 2016 Jan 03; 381(1). PMID: 26723878    Free PMC article.
Highly Cited. Review.
Opportunities and challenges in combination gene cancer therapy.
Kent L Nastiuk, John J Krolewski.
Adv Drug Deliv Rev, 2016 Jan 03; 98. PMID: 26724249    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma.
M Kudo.
Liver Cancer, 2016 Jan 07; 4(4). PMID: 26732472    Free PMC article.
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer.
Karen Weintraub.
Nat Med, 2016 Jan 07; 22(1). PMID: 26735398
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential.
Gregory T Wurz, Chiao-Jung Kao, Michael W DeGregorio.
Ther Adv Med Oncol, 2016 Jan 12; 8(1). PMID: 26753003    Free PMC article.
Influence of immunoglobulin isotype on therapeutic antibody function.
Stephen A Beers, Martin J Glennie, Ann L White.
Blood, 2016 Jan 15; 127(9). PMID: 26764357    Free PMC article.
Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.
Adarsh Vennepureddy, Nishitha Thumallapally, +2 authors, Terenig Terjanian.
J Clin Med Res, 2016 Jan 15; 8(2). PMID: 26767073    Free PMC article.
Bridging academic science and clinical research in the search for novel targeted anti-cancer agents.
Alex Matter.
Cancer Biol Med, 2016 Jan 19; 12(4). PMID: 26779369    Free PMC article.
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
Zhong-Yi Dong, Si-Pei Wu, +2 authors, Yi-Long Wu.
Tumour Biol, 2016 Jan 19; 37(4). PMID: 26779629
Updates in Therapy for Advanced Melanoma.
Bhavana P Singh, April K S Salama.
Cancers (Basel), 2016 Jan 20; 8(1). PMID: 26784231    Free PMC article.
Melanoma in 2015: Immune-checkpoint blockade - durable cancer control.
Elizabeth I Buchbinder, F Stephen Hodi.
Nat Rev Clin Oncol, 2016 Jan 21; 13(2). PMID: 26787285
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
Jianda Yuan, Priti S Hegde, +16 authors, Bernard A Fox.
J Immunother Cancer, 2016 Jan 21; 4. PMID: 26788324    Free PMC article.
Highly Cited. Review.
Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
S Diem, B Kasenda, +4 authors, J Larkin.
Br J Cancer, 2016 Jan 23; 114(3). PMID: 26794281    Free PMC article.
Highly Cited.
Immunotherapy meets targeted therapy: will this team end the war against cancer?
Daniela Morales-Espinosa, Silvia García-Román, +2 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798584    Free PMC article.
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer.
Santiago Viteri, María González-Cao, +2 authors, Rafael Rosell.
Transl Lung Cancer Res, 2016 Jan 23; 4(6). PMID: 26798585    Free PMC article.
The role of microbiota in cancer therapy.
Ernesto Perez-Chanona, Giorgio Trinchieri.
Curr Opin Immunol, 2016 Jan 29; 39. PMID: 26820225    Free PMC article.
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy.
Douglas B Johnson, Monica V Estrada, +18 authors, Justin M Balko.
Nat Commun, 2016 Jan 30; 7. PMID: 26822383    Free PMC article.
Highly Cited.
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
Patrick J Medina, Val R Adams.
Pharmacotherapy, 2016 Jan 30; 36(3). PMID: 26822752    Free PMC article.
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent.
Pan Pantziarka, Vidula Sukhatme, +2 authors, Vikas P Sukhatme.
Ecancermedicalscience, 2016 Jan 30; 10. PMID: 26823679    Free PMC article.
Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
Iris Eke, Adeola Y Makinde, +2 authors, C Norman Coleman.
Cancer Lett, 2016 Oct 22; 382(1). PMID: 26828133    Free PMC article.
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, Yosef Yarden.
Br J Pharmacol, 2016 Feb 03; 173(9). PMID: 26833433    Free PMC article.
Pembrolizumab: A Review in Advanced Melanoma.
Emma D Deeks.
Drugs, 2016 Feb 06; 76(3). PMID: 26846323
Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
Don S Dizon, Lada Krilov, +17 authors, Gregory Masters.
J Clin Oncol, 2016 Feb 06; 34(9). PMID: 26846975    Free PMC article.
Highly Cited.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Scott Antonia, Sarah B Goldberg, +8 authors, Naiyer A Rizvi.
Lancet Oncol, 2016 Feb 10; 17(3). PMID: 26858122    Free PMC article.
Highly Cited.
Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2?
Lidia Robert, Antoni Ribas, Siwen Hu-Lieskovan.
Semin Immunol, 2016 Feb 11; 28(1). PMID: 26861544    Free PMC article.
CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell-Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1.
Yunqin Lee, June Ho Shin, +4 authors, John B Sunwoo.
Clin Cancer Res, 2016 Feb 13; 22(14). PMID: 26864211    Free PMC article.
Highly Cited.
Improving the clinical impact of biomaterials in cancer immunotherapy.
Joshua M Gammon, Neil M Dold, Christopher M Jewell.
Oncotarget, 2016 Feb 13; 7(13). PMID: 26871948    Free PMC article.
Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma.
William T Curry, Ramana Gorrepati, +9 authors, Glenn Dranoff.
Clin Cancer Res, 2016 Feb 14; 22(12). PMID: 26873960    Free PMC article.
Low temperature plasmas as emerging cancer therapeutics: the state of play and thoughts for the future.
Adam M Hirst, Fiona M Frame, +2 authors, Deborah O'Connell.
Tumour Biol, 2016 Feb 19; 37(6). PMID: 26888782    Free PMC article.
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy.
Wang Jing, Miaomiao Li, +4 authors, Hui Zhu.
Onco Targets Ther, 2016 Feb 19; 9. PMID: 26889087    Free PMC article.
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Paola Savoia, Chiara Astrua, Paolo Fava.
Hum Vaccin Immunother, 2016 Feb 19; 12(5). PMID: 26889818    Free PMC article.
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Junzo Hamanishi, Masaki Mandai, +3 authors, Ikuo Konishi.
Int J Clin Oncol, 2016 Feb 24; 21(3). PMID: 26899259    Free PMC article.
Highly Cited. Review.
Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients.
Alena Gros, Maria R Parkhurst, +11 authors, Steven A Rosenberg.
Nat Med, 2016 Feb 24; 22(4). PMID: 26901407    Free PMC article.
Highly Cited.
High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.
Suresh Gopi Kalathil, Yasmin Thanavala.
Cancer Immunol Immunother, 2016 Feb 26; 65(7). PMID: 26910314    Free PMC article.
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Stefani Spranger, Ayelet Sivan, Leticia Corrales, Thomas F Gajewski.
Adv Immunol, 2016 Mar 01; 130. PMID: 26923000    Free PMC article.
Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities.
K M Morrissey, T M Yuraszeck, +2 authors, S Kasichayanula.
Clin Transl Sci, 2016 Mar 01; 9(2). PMID: 26924066    Free PMC article.
Highly Cited. Review.
Novel targets in the treatment of advanced gastric cancer: a perspective review.
Elisa Fontana, Elizabeth C Smyth.
Ther Adv Med Oncol, 2016 Mar 02; 8(2). PMID: 26929787    Free PMC article.
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations.
Weiping Zou, Jedd D Wolchok, Lieping Chen.
Sci Transl Med, 2016 Mar 05; 8(328). PMID: 26936508    Free PMC article.
Highly Cited. Review.
Doubling the blockade for melanoma immunotherapy.
Lorenzo Galluzzi, Alexander Eggermont, Guido Kroemer.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942094    Free PMC article.
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
Omar Abdel-Rahman, Mona Fouad.
Ther Adv Respir Dis, 2016 Mar 06; 10(3). PMID: 26944362    Free PMC article.
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
Jonathan E Rosenberg, Jean Hoffman-Censits, +28 authors, Robert Dreicer.
Lancet, 2016 Mar 10; 387(10031). PMID: 26952546    Free PMC article.
Highly Cited.
HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.
Hong Zheng, Weipeng Zhao, +13 authors, Amer A Beg.
Clin Cancer Res, 2016 Mar 12; 22(16). PMID: 26964571    Free PMC article.
Highly Cited.
Vaccines for established cancer: overcoming the challenges posed by immune evasion.
Sjoerd H van der Burg, Ramon Arens, +2 authors, Cornelis J M Melief.
Nat Rev Cancer, 2016 Mar 12; 16(4). PMID: 26965076
Highly Cited. Review.
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Axel Hoos.
Nat Rev Drug Discov, 2016 Mar 12; 15(4). PMID: 26965203
Highly Cited.
The Basis of Oncoimmunology.
A Karolina Palucka, Lisa M Coussens.
Cell, 2016 Mar 12; 164(6). PMID: 26967289    Free PMC article.
Highly Cited. Review.
A primer on tumour immunology and prostate cancer immunotherapy.
Runhan Ren, Madhuri Koti, +5 authors, D Robert Siemens.
Can Urol Assoc J, 2016 Mar 16; 10(1-2). PMID: 26977209    Free PMC article.
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.
Danny N Khalil, Eric L Smith, Renier J Brentjens, Jedd D Wolchok.
Nat Rev Clin Oncol, 2016 Mar 16; 13(5). PMID: 26977780    Free PMC article.
Highly Cited. Review.
The State of Cancer Care in America, 2016: A Report by the American Society of Clinical Oncology.
American Society of Clinical Oncology.
J Oncol Pract, 2016 Mar 17; 12(4). PMID: 26979926    Free PMC article.
Highly Cited.
The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines.
Xiuwen Guan, Haijuan Wang, +3 authors, Binghe Xu.
Medicine (Baltimore), 2016 Mar 18; 95(11). PMID: 26986169    Free PMC article.
Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment.
Stefani Spranger.
Int Immunol, 2016 Mar 19; 28(8). PMID: 26989092    Free PMC article.
Highly Cited. Review.
MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells.
Mario Martínez Soldevilla, Helena Villanueva, +5 authors, Fernando Pastor.
Oncotarget, 2016 Mar 19; 7(17). PMID: 26992239    Free PMC article.
Repurposing metformin for cancer treatment: current clinical studies.
Young Kwang Chae, Ayush Arya, +8 authors, Francis Giles.
Oncotarget, 2016 Oct 27; 7(26). PMID: 27004404    Free PMC article.
Highly Cited. Review.
Immune evasion pathways and the design of dendritic cell-based cancer vaccines.
Brent A Hanks.
Discov Med, 2016 Mar 25; 21(114). PMID: 27011049    Free PMC article.
Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance.
Kuo-Hsing Chen, Chang-Tsu Yuan, +2 authors, Kun-Huei Yeh.
J Hematol Oncol, 2016 Mar 26; 9. PMID: 27012666    Free PMC article.
Clinical utility of nivolumab in the treatment of advanced melanoma.
Ramsey Asmar, Jessica Yang, Richard D Carvajal.
Ther Clin Risk Manag, 2016 Mar 26; 12. PMID: 27013881    Free PMC article.
Targeting melanoma with immunoliposomes coupled to anti-MAGE A1 TCR-like single-chain antibody.
Mesha Saeed, Mandy van Brakel, +5 authors, Timo L M Ten Hagen.
Int J Nanomedicine, 2016 Mar 30; 11. PMID: 27022262    Free PMC article.
Into the Clinic With Nivolumab and Pembrolizumab.
Catherine A Shu, Naiyer A Rizvi.
Oncologist, 2016 Mar 31; 21(5). PMID: 27026678    Free PMC article.
Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.
Christian S Hinrichs.
Clin Cancer Res, 2016 Apr 03; 22(7). PMID: 27037253    Free PMC article.
Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Laura Graham, Michael T Schweizer.
Med Oncol, 2016 Apr 05; 33(5). PMID: 27042852
Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
V R Belum, B Benhuri, +8 authors, M E Lacouture.
Eur J Cancer, 2016 Apr 05; 60. PMID: 27043866    Free PMC article.
Highly Cited. Systematic Review.
Combination therapy for metastatic renal cell carcinoma.
Carlo Buonerba, Giuseppe Di Lorenzo, Guru Sonpavde.
Ann Transl Med, 2016 Apr 06; 4(5). PMID: 27047959    Free PMC article.
The role of neoantigens in response to immune checkpoint blockade.
Nadeem Riaz, Luc Morris, +3 authors, Timothy A Chan.
Int Immunol, 2016 Apr 07; 28(8). PMID: 27048318    Free PMC article.
The efficacy and safety of nivolumab in the treatment of advanced melanoma: a meta-analysis of clinical trials.
Conghui Jin, Xunlei Zhang, +3 authors, Xiaohong Xu.
Onco Targets Ther, 2016 Apr 07; 9. PMID: 27051297    Free PMC article.
Immunotherapy for cancer in the central nervous system: Current and future directions.
David C Binder, Andrew A Davis, Derek A Wainwright.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057463    Free PMC article.
Highly Cited. Review.
Therapeutic implications of melanoma heterogeneity.
Stephanie J Hachey, Alexander D Boiko.
Exp Dermatol, 2016 Apr 12; 25(7). PMID: 27060971    Free PMC article.
Cocktails for cancer with a measure of immunotherapy.
Heidi Ledford.
Nature, 2016 Apr 15; 532(7598). PMID: 27075078
Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition.
Jurjen Tel, Rutger Koornstra, +9 authors, Stanleyson V Hato.
J Transl Med, 2016 Apr 15; 14. PMID: 27075584    Free PMC article.
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll.
Nat Rev Cancer, 2016 Apr 16; 16(5). PMID: 27079802    Free PMC article.
Highly Cited. Review.
Off-label use of targeted therapies in oncology.
Dominique Levêque.
World J Clin Oncol, 2016 Apr 16; 7(2). PMID: 27081648    Free PMC article.
Adapting Cancer Immunotherapy Models for the Real World.
Lauryn E Klevorn, Ryan M Teague.
Trends Immunol, 2016 Apr 24; 37(6). PMID: 27105824    Free PMC article.
Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.
Andries Blokzijl, Lei E Chen, +6 authors, Håkan Hedstrand.
PLoS One, 2016 Apr 26; 11(4). PMID: 27110718    Free PMC article.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
PD-L1 Expression in Lung Cancer.
Hui Yu, Theresa A Boyle, +2 authors, Fred R Hirsch.
J Thorac Oncol, 2016 Apr 28; 11(7). PMID: 27117833    Free PMC article.
Highly Cited. Review.
[Renaissance of immuno-oncology for urological tumors : Current status].
M-O Grimm, Y Winkler, I Fetter, H Oppel-Heuchel.
Urologe A, 2016 Apr 28; 55(5). PMID: 27119960
B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Juan Ma, Pan Ma, +7 authors, Man Zhang.
Oncotarget, 2016 Apr 29; 7(20). PMID: 27121051    Free PMC article.
Immune based therapy for melanoma.
Robert Ancuceanu, Monica Neagu.
Indian J Med Res, 2016 Apr 29; 143(2). PMID: 27121512    Free PMC article.
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
S Bowyer, P Prithviraj, +17 authors, O Klein.
Br J Cancer, 2016 Apr 29; 114(10). PMID: 27124339    Free PMC article.
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq.
Itay Tirosh, Benjamin Izar, +34 authors, Levi A Garraway.
Science, 2016 Apr 29; 352(6282). PMID: 27124452    Free PMC article.
Highly Cited.
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.
Arun Rajan, Chul Kim, +2 authors, James L Gulley.
Hum Vaccin Immunother, 2016 May 03; 12(9). PMID: 27135835    Free PMC article.
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories.
Ping Qiu, Ling Pang, +4 authors, Diane Levitan.
Int J Mol Sci, 2016 May 03; 17(5). PMID: 27136543    Free PMC article.
Quantifying Treatment Benefit in Molecular Subgroups to Assess a Predictive Biomarker.
Alexia Iasonos, Paul B Chapman, Jaya M Satagopan.
Clin Cancer Res, 2016 May 04; 22(9). PMID: 27141007    Free PMC article.
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Celine Boutros, Ahmad Tarhini, +14 authors, Caroline Robert.
Nat Rev Clin Oncol, 2016 May 05; 13(8). PMID: 27141885
Highly Cited. Review.
Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma.
Megan L Ludwig, Andrew C Birkeland, +3 authors, J Chad Brenner.
Cancer Biol Med, 2016 May 05; 13(1). PMID: 27144065    Free PMC article.
Pembrolizumab in classical Hodgkin's lymphoma.
Joseph Maly, Lapo Alinari.
Eur J Haematol, 2016 May 06; 97(3). PMID: 27147112    Free PMC article.
Sequential treatment with immunotherapy and BRAF inhibitors in BRAF-mutant advanced melanoma.
F Aya, A Fernandez-Martinez, +6 authors, A Arance.
Clin Transl Oncol, 2016 May 06; 19(1). PMID: 27147251
A framework for understanding and targeting residual disease in oncogene-driven solid cancers.
Trever G Bivona, Robert C Doebele.
Nat Med, 2016 May 07; 22(5). PMID: 27149220    Free PMC article.
Highly Cited.
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer.
Janice M Mehnert, Anshuman Panda, +16 authors, Shridar Ganesan.
J Clin Invest, 2016 May 10; 126(6). PMID: 27159395    Free PMC article.
Highly Cited.
Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Paula Kroon, Jules Gadiot, +7 authors, Inge Verbrugge.
Cancer Immunol Immunother, 2016 May 11; 65(6). PMID: 27160390    Free PMC article.
Roles of regulatory T cells in cancer immunity.
Yoshiko Takeuchi, Hiroyoshi Nishikawa.
Int Immunol, 2016 May 11; 28(8). PMID: 27160722    Free PMC article.
Highly Cited. Review.
HemOnc Today Melanoma and Cutaneous Malignancies and American College of Cardiology.
Walter Alexander.
P T, 2016 May 11; 41(5). PMID: 27162474    Free PMC article.
[Systemic treatment of inoperable metastasized malignant melanoma].
R Gutzmer, R Rauschenberg, F Meier.
Hautarzt, 2016 May 12; 67(7). PMID: 27164828
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.
Alexander Martens, Kilian Wistuba-Hamprecht, +15 authors, Benjamin Weide.
Clin Cancer Res, 2016 May 14; 22(19). PMID: 27169993    Free PMC article.
Highly Cited.
T cell Bim levels reflect responses to anti-PD-1 cancer therapy.
Roxana S Dronca, Xin Liu, +11 authors, Haidong Dong.
JCI Insight, 2016 May 18; 1(6). PMID: 27182556    Free PMC article.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.
Giampaolo Bianchini, Justin M Balko, +2 authors, Luca Gianni.
Nat Rev Clin Oncol, 2016 Oct 19; 13(11). PMID: 27184417    Free PMC article.
Highly Cited. Review.
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Marco Puzzoni, Nicola Silvestris, +13 authors, Mario Scartozzi.
Target Oncol, 2016 May 18; 11(5). PMID: 27184491
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.
Benjamin Weide, Alexander Martens, +24 authors, Jedd D Wolchok.
Clin Cancer Res, 2016 Nov 01; 22(22). PMID: 27185375    Free PMC article.
Highly Cited.
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.
Shi-Dong Ma, Xuequn Xu, +5 authors, Shannon C Kenney.
PLoS Pathog, 2016 May 18; 12(5). PMID: 27186886    Free PMC article.
Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer.
Hong Zheng, Xin Liu, +7 authors, Chandra P Belani.
Oncotarget, 2016 May 19; 7(35). PMID: 27191652    Free PMC article.
Programmed death-ligand-1 expression in advanced gastric cancer detected with RNA in situ hybridization and its clinical significance.
Jiajia Yuan, Jie Zhang, +8 authors, Lin Shen.
Oncotarget, 2016 Oct 26; 7(26). PMID: 27191996    Free PMC article.
PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion.
Roberto Tinoco, Florent Carrette, +5 authors, Linda M Bradley.
Immunity, 2016 May 19; 44(5). PMID: 27192578    Free PMC article.
Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses.
Leandro M Colli, Mitchell J Machiela, +3 authors, Stephen J Chanock.
Cancer Res, 2016 May 20; 76(13). PMID: 27197178    Free PMC article.
Highly Cited.
Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.
Manuela Terranova-Barberio, Scott Thomas, Pamela N Munster.
Immunotherapy, 2016 May 21; 8(6). PMID: 27197539    Free PMC article.
microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.
Keith M Giles, Rikki A M Brown, +10 authors, Peter J Leedman.
Oncotarget, 2016 May 21; 7(22). PMID: 27203220    Free PMC article.
Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma.
Mark R Albertini, Erik A Ranheim, +12 authors, Uri Galili.
Cancer Immunol Immunother, 2016 May 22; 65(8). PMID: 27207605    Free PMC article.
CIS is a potent checkpoint in NK cell-mediated tumor immunity.
Rebecca B Delconte, Tatiana B Kolesnik, +29 authors, Nicholas D Huntington.
Nat Immunol, 2016 May 24; 17(7). PMID: 27213690
Highly Cited.
Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.
Stephanie L Goff, Mark E Dudley, +22 authors, Steven A Rosenberg.
J Clin Oncol, 2016 May 25; 34(20). PMID: 27217459    Free PMC article.
Highly Cited.
Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients.
Steve Boudewijns, Harm Westdorp, +8 authors, Kalijn F Bol.
J Immunother, 2016 May 27; 39(6). PMID: 27227325    Free PMC article.
Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?
Lucia Festino, Gerardo Botti, +5 authors, Paolo A Ascierto.
Drugs, 2016 May 28; 76(9). PMID: 27229745
Highly Cited. Review.
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy.
Benjamin M Larimer, Eric Wehrenberg-Klee, Alexander Caraballo, Umar Mahmood.
J Nucl Med, 2016 May 28; 57(10). PMID: 27230929    Free PMC article.
State of the science on prevention and screening to reduce melanoma incidence and mortality: The time is now.
Mary K Tripp, Meg Watson, +2 authors, Jeffrey E Gershenwald.
CA Cancer J Clin, 2016 May 28; 66(6). PMID: 27232110    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Checkpoint Inhibitors and Their Application in Breast Cancer.
Davide Bedognetti, Cristina Maccalli, +2 authors, Barbara Seliger.
Breast Care (Basel), 2016 May 31; 11(2). PMID: 27239172    Free PMC article.
Current clinical immunotherapeutic approaches for head and neck cancer.
Carolina Soto Chervin, Bruce Brockstein.
F1000Res, 2016 May 31; 5. PMID: 27239282    Free PMC article.
Multiple Inhibitory Pathways Contribute to Lung CD8+ T Cell Impairment and Protect against Immunopathology during Acute Viral Respiratory Infection.
John J Erickson, Meredith C Rogers, +2 authors, John V Williams.
J Immunol, 2016 Jun 05; 197(1). PMID: 27259857    Free PMC article.
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Jeffrey S Weber, Geoff Gibney, +14 authors, F Stephen Hodi.
Lancet Oncol, 2016 Jun 09; 17(7). PMID: 27269740    Free PMC article.
Highly Cited.
[Molecular and immunohistochemical diagnostics in melanoma].
B Schilling, K G Griewank.
Hautarzt, 2016 Jun 09; 67(7). PMID: 27270408
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.
Naoka Murakami, Thiago J Borges, Michifumi Yamashita, Leonardo V Riella.
Clin Kidney J, 2016 Jun 09; 9(3). PMID: 27274826    Free PMC article.
Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside.
R Bhome, H A Al Saihati, +5 authors, A H Mirnezami.
New Horiz Transl Med, 2016 Jun 09; 3(1). PMID: 27275004    Free PMC article.
What does the future hold for immunotherapy in cancer?
Jarushka Naidoo, Bob T Li, Katja Schindler, David B Page.
Ann Transl Med, 2016 Jun 09; 4(9). PMID: 27275490    Free PMC article.
Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery.
Jack M Qian, James B Yu, Harriet M Kluger, Veronica L S Chiang.
Cancer, 2016 Jun 11; 122(19). PMID: 27285122    Free PMC article.
Highly Cited.
Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies.
Woo Young Sun, Yu Kyung Lee, Ja Seung Koo.
J Transl Med, 2016 Jun 12; 14(1). PMID: 27286842    Free PMC article.
Immune Checkpoint Inhibitors in Older Adults.
Rawad Elias, Joshua Morales, Yasser Rehman, Humera Khurshid.
Curr Oncol Rep, 2016 Jun 12; 18(8). PMID: 27287329
The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.
P R Lowenstein, M G Castro.
Adv Pharmacol, 2016 Jun 12; 76. PMID: 27288077    Free PMC article.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
Elisa González-Rodríguez, Delvys Rodríguez-Abreu, Spanish Group for Cancer Immuno-Biotherapy (GETICA).
Oncologist, 2016 Jun 17; 21(7). PMID: 27306911    Free PMC article.
Highly Cited. Review.
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab.
Laura C Cappelli, Anna Kristina Gutierrez, +10 authors, Clifton O Bingham.
Ann Rheum Dis, 2016 Jun 17; 76(1). PMID: 27307501    Free PMC article.
Highly Cited.
Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer.
Dionisia Quiroga, H Kim Lyerly, Michael A Morse.
Curr Treat Options Oncol, 2016 Jun 18; 17(8). PMID: 27315067
Emerging targets for radioprotection and radiosensitization in radiotherapy.
Sumit Kumar, Rajnish Kumar Singh, Ramovatar Meena.
Tumour Biol, 2016 Oct 27; 37(9). PMID: 27318945
Dendritic cell vaccination in melanoma patients: From promising results to future perspectives.
Steve Boudewijns, Martine Bloemendal, +2 authors, Gerty Schreibelt.
Hum Vaccin Immunother, 2016 Jun 21; 12(10). PMID: 27322496    Free PMC article.
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Maria I Carlo, Martin H Voss, Robert J Motzer.
Nat Rev Urol, 2016 Jun 22; 13(7). PMID: 27324121    Free PMC article.
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody.
Mehmet Asim Bilen, Sumit K Subudhi, +3 authors, Padmanee Sharma.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330809    Free PMC article.
Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule.
Howard L Kaufman, Lisa H Butterfield, +9 authors, Francesco M Marincola.
J Immunother Cancer, 2016 Jun 23; 4. PMID: 27330810    Free PMC article.
Combined immunotherapy and radiation for treatment of mucosal melanomas of the lower genital tract.
Maria B Schiavone, Vance Broach, +5 authors, Mario M Leitao.
Gynecol Oncol Rep, 2016 Jun 23; 16. PMID: 27331137    Free PMC article.
Molecular characterisation of cutaneous melanoma: creating a framework for targeted and immune therapies.
Shivshankari Rajkumar, Ian R Watson.
Br J Cancer, 2016 Jun 24; 115(2). PMID: 27336610    Free PMC article.
Advanced Hepatocellular Cancer: the Current State of Future Research.
Louise C Connell, James J Harding, Ghassan K Abou-Alfa.
Curr Treat Options Oncol, 2016 Jun 28; 17(8). PMID: 27344158
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
S Chouaib, M Z Noman, K Kosmatopoulos, M A Curran.
Oncogene, 2016 Jun 28; 36(4). PMID: 27345407    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Chrisann Kyi, Michael A Postow.
Immunotherapy, 2016 Jun 29; 8(7). PMID: 27349981    Free PMC article.
Highly Cited. Review.
CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.
Zhenhua Ren, Jingya Guo, +7 authors, Yang-Xin Fu.
Clin Cancer Res, 2016 Jun 30; 23(1). PMID: 27354469    Free PMC article.
The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Leora Horn, Martin Reck, David R Spigel.
Oncologist, 2016 Jun 30; 21(8). PMID: 27354668    Free PMC article.
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas.
Jennifer E Kim, Mira A Patel, +23 authors, Michael Lim.
Clin Cancer Res, 2016 Jul 01; 23(1). PMID: 27358487    Free PMC article.
Highly Cited.
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials.
Fausto Petrelli, Andrea Coinu, +4 authors, Sandro Barni.
Medicine (Baltimore), 2016 Jul 02; 95(26). PMID: 27368007    Free PMC article.
Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer.
S Bidnur, R Savdie, P C Black.
Bladder Cancer, 2016 Jul 05; 2(1). PMID: 27376121    Free PMC article.
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer.
Seth P Lerner, Dean F Bajorin, +33 authors, Diane Zipursky Quale.
Bladder Cancer, 2016 Jul 05; 2(2). PMID: 27376138    Free PMC article.
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
Juanita S Lopez, Udai Banerji.
Nat Rev Clin Oncol, 2016 Nov 03; 14(1). PMID: 27377132    Free PMC article.
Highly Cited. Review.
The current status of checkpoint inhibitors in metastatic bladder cancer.
Omar Fahmy, Mohd Ghani Khairul-Asri, Arnulf Stenzl, Georgios Gakis.
Clin Exp Metastasis, 2016 Jul 07; 33(7). PMID: 27380916
Systematic Review.
Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Natalie Vandeven, Paul Nghiem.
Immunotherapy, 2016 Jul 07; 8(8). PMID: 27381685    Free PMC article.
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.
Giuseppe Santabarbara, Paolo Maione, +2 authors, Cesare Gridelli.
Ann Transl Med, 2016 Jul 08; 4(11). PMID: 27386489    Free PMC article.
Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALBc mice.
Agustina Roldan-Deamicis, Eliana Alonso, +2 authors, Gabriela Andrea Balogh.
Cancer Med, 2016 Jul 13; 5(9). PMID: 27401257    Free PMC article.
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Michihisa Moriguchi, Atsushi Umemura, Yoshito Itoh.
Clin J Gastroenterol, 2016 Jul 13; 9(4). PMID: 27401471
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Jeffrey S Weber, Michael Postow, Christopher D Lao, Dirk Schadendorf.
Oncologist, 2016 Jul 13; 21(10). PMID: 27401894    Free PMC article.
Highly Cited. Review.
Systemic therapy for bladder cancer finally comes into a new age.
Matthew Zibelman, Elizabeth R Plimack.
Future Oncol, 2016 Jul 13; 12(19). PMID: 27402371    Free PMC article.
Merkel Cell Carcinoma: An Unusually Immunogenic Cancer Proves Ripe for Immune Therapy.
Natalie A Vandeven, Paul Nghiem.
J Oncol Pract, 2016 Jul 14; 12(7). PMID: 27407162    Free PMC article.
Recent advances in molecular genetics of melanoma progression: implications for diagnosis and treatment.
Iwei Yeh.
F1000Res, 2016 Jul 14; 5. PMID: 27408703    Free PMC article.
Tumor infiltrating lymphocytes and PD-L1 expression in brain metastases of small cell lung cancer (SCLC).
Anna Sophie Berghoff, Gerda Ricken, +6 authors, Matthias Preusser.
J Neurooncol, 2016 Oct 21; 130(1). PMID: 27436101
Cancer immunotherapy trials: leading a paradigm shift in drug development.
Leisha A Emens, Lisa H Butterfield, +2 authors, Howard L Kaufman.
J Immunother Cancer, 2016 Jul 21; 4. PMID: 27437105    Free PMC article.
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.
Eric D Brooks, Jonathan E Schoenhals, +4 authors, James W Welsh.
Cancer J, 2016 Jul 22; 22(4). PMID: 27441745    Free PMC article.
Advances in immunotherapy for melanoma management.
Mohammed Dany, Rose Nganga, +3 authors, Dirk Elston.
Hum Vaccin Immunother, 2016 Jul 28; 12(10). PMID: 27454404    Free PMC article.
Stem-like features of cancer cells on their way to metastasis.
Sofia Gkountela, Nicola Aceto.
Biol Direct, 2016 Jul 28; 11. PMID: 27457474    Free PMC article.
Immuno-oncology combinations: raising the tail of the survival curve.
Samuel J Harris, Jessica Brown, Juanita Lopez, Timothy A Yap.
Cancer Biol Med, 2016 Jul 28; 13(2). PMID: 27458526    Free PMC article.
The Promise of Molecularly Targeted and Immunotherapy for Advanced Melanoma.
Kim Margolin.
Curr Treat Options Oncol, 2016 Jul 28; 17(9). PMID: 27461037
An update on clinical oncology for the non-oncologist.
Rafael Aliosha Kaliks.
Einstein (Sao Paulo), 2016 Jul 28; 14(2). PMID: 27462901    Free PMC article.
PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations.
Andreas H Scheel, Sascha Ansén, +14 authors, Jürgen Wolf.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467949    Free PMC article.
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma.
Ioannis Karydis, Pui Ying Chan, +3 authors, Christian H Ottensmeier.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467964    Free PMC article.
Cancer of the Pancreas: Molecular Pathways and Current Advancement in Treatment.
Kishore Polireddy, Qi Chen.
J Cancer, 2016 Jul 30; 7(11). PMID: 27471566    Free PMC article.
Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis.
Katharina Lankes, Gheorghe Hundorfean, +9 authors, Lucie Heinzerling.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471608    Free PMC article.
Prioritization schema for immunotherapy clinical trials in glioblastoma.
Tiffany R Hodges, Sherise D Ferguson, +17 authors, Amy B Heimberger.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471611    Free PMC article.
Biomarkers of immunogenic stress in metastases from melanoma patients: Correlations with the immune infiltrate.
Sylvain Ladoire, Laura Senovilla, +9 authors, Guido Kroemer.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471635    Free PMC article.
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.
Wei Xue, Rachael L Metheringham, +5 authors, Lindy G Durrant.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471648    Free PMC article.
PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
Zhijuan Lin, Xing Chen, +4 authors, Mingzhe Han.
PLoS One, 2016 Aug 03; 11(8). PMID: 27483468    Free PMC article.
Systematic Review.
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Raffaele Califano, Keith Kerr, +4 authors, Antonio Rossi.
Curr Oncol Rep, 2016 Aug 04; 18(9). PMID: 27484062
Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.
Benedetto Farsaci, Renee N Donahue, +9 authors, Jeffrey Schlom.
Cancer Immunol Res, 2016 Aug 04; 4(9). PMID: 27485137    Free PMC article.
Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy.
Kathleen C Suozzi, Maximilian Stahl, +4 authors, Christopher G Bunick.
JAAD Case Rep, 2016 Aug 04; 2(3). PMID: 27486590    Free PMC article.
Medical treatment of renal cancer: new horizons.
Basma Greef, Tim Eisen.
Br J Cancer, 2016 Aug 05; 115(5). PMID: 27490806    Free PMC article.
Oncolytic viruses-immunotherapeutics on the rise.
Brian A Keller, John C Bell.
J Mol Med (Berl), 2016 Aug 06; 94(9). PMID: 27492706
Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
David Gill, Andrew W Hahn, Guru Sonpavde, Neeraj Agarwal.
Hum Vaccin Immunother, 2016 Aug 06; 12(12). PMID: 27494417    Free PMC article.
Delay in cutaneous melanoma diagnosis: Sequence analyses from suspicion to diagnosis in 211 patients.
Marcus H S B Xavier, Ana P Drummond-Lage, +3 authors, Alberto J A Wainstein.
Medicine (Baltimore), 2016 Aug 09; 95(31). PMID: 27495055    Free PMC article.
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Lewis Zhichang Shi, Tihui Fu, +7 authors, Padmanee Sharma.
Nat Commun, 2016 Aug 09; 7. PMID: 27498556    Free PMC article.
Immunoproteasomes and immunotherapy-a smoking gun for lung cancer?
Menno Spits, Jacques Neefjes.
J Thorac Dis, 2016 Aug 09; 8(7). PMID: 27501321    Free PMC article.
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
Maria Del Castillo, Fabian A Romero, +3 authors, Gil Redelman-Sidi.
Clin Infect Dis, 2016 Aug 10; 63(11). PMID: 27501841    Free PMC article.
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy.
J F Novotny, J Cogswell, +3 authors, S Averbuch.
Ann Oncol, 2016 Aug 10; 27(10). PMID: 27502705    Free PMC article.
Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells.
Dhifaf Sarhan, Frank Cichocki, +6 authors, Jeffrey S Miller.
Cancer Res, 2016 Aug 10; 76(19). PMID: 27503932    Free PMC article.
Novel melanoma therapy.
Eddy C Hsueh, Kalyan C Gorantla.
Exp Hematol Oncol, 2015 Jan 01; 5. PMID: 27508107    Free PMC article.
[Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
A H Scheel, M Dietel, +12 authors, R Büttner.
Pathologe, 2016 Oct 28; 37(6). PMID: 27510417
Sequencing of New and Old Therapies for Metastatic Melanoma.
Megan Ratterman, Sigrun Hallmeyer, Jon Richards.
Curr Treat Options Oncol, 2016 Aug 16; 17(10). PMID: 27515170
Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.
Aung Naing, Kyriakos P Papadopoulos, +17 authors, Jeffrey R Infante.
J Clin Oncol, 2016 Aug 17; 34(29). PMID: 27528724    Free PMC article.
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma.
Asim Amin, David H Lawson, +8 authors, F Stephen Hodi.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532019    Free PMC article.
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg, Naiyer A Rizvi.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532023    Free PMC article.
Highly Cited. Review.
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
Lucie Heinzerling, Patrick A Ott, +7 authors, Jason J Luke.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532025    Free PMC article.
Highly Cited.
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Alain P Algazi, Katy K Tsai, +13 authors, Ryan J Sullivan.
Cancer, 2016 Oct 21; 122(21). PMID: 27533448    Free PMC article.
Highly Cited.
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Alexander N Shoushtari, Rodrigo R Munhoz, +17 authors, Michael A Postow.
Cancer, 2016 Oct 21; 122(21). PMID: 27533633    Free PMC article.
Highly Cited.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.
Mizuki Nishino, Nikhil H Ramaiya, +7 authors, F Stephen Hodi.
Clin Cancer Res, 2016 Aug 19; 22(24). PMID: 27535979    Free PMC article.
Highly Cited.
New targeted treatments for non-small-cell lung cancer - role of nivolumab.
Giulia Zago, Mirte Muller, Michel van den Heuvel, Paul Baas.
Biologics, 2016 Aug 19; 10. PMID: 27536062    Free PMC article.
Current Progress in Immunotherapy for the Treatment of Biliary Cancers.
James M Pauff, Laura W Goff.
J Gastrointest Cancer, 2016 Aug 20; 47(4). PMID: 27538880
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
Michiel van der Vlist, Jurgen Kuball, Timothy R D Radstake, Linde Meyaard.
Nat Rev Rheumatol, 2016 Aug 20; 12(10). PMID: 27539666
Evaluating cost benefits of combination therapies for advanced melanoma.
Ivar S Jensen, Emily Zacherle, +2 authors, Wes Yin.
Drugs Context, 2016 Aug 20; 5. PMID: 27540409    Free PMC article.
A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
Jennifer L McQuade, Liberty P Posada, +8 authors, Rodabe N Amaria.
Melanoma Res, 2016 Oct 26; 26(6). PMID: 27540836    Free PMC article.
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysis.
Yufan Yang, ZhaoFei Pang, +5 authors, Qi Liu.
Oncotarget, 2016 Aug 20; 7(45). PMID: 27542277    Free PMC article.
Systematic Review.
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
Chao Wang, Wujin Sun, +2 authors, Zhen Gu.
Adv Mater, 2016 Oct 21; 28(40). PMID: 27558441    Free PMC article.
Harnessing the immune system to improve cancer therapy.
Nikos E Papaioannou, Ourania V Beniata, +2 authors, Pinelopi Samara.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563648    Free PMC article.
Highly Cited. Review.
DNA damage, tumor mutational load and their impact on immune responses against cancer.
Michalis Liontos, Ioannis Anastasiou, Aristotelis Bamias, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563651    Free PMC article.
Melanoma immunotherapy dominates the field.
Panagiotis Diamantopoulos, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563656    Free PMC article.
Toxicity management of immunotherapy for patients with metastatic melanoma.
Helena Linardou, Helen Gogas.
Ann Transl Med, 2016 Aug 27; 4(14). PMID: 27563659    Free PMC article.
Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Kazuhiko Shien, Vassiliki A Papadimitrakopoulou, Ignacio I Wistuba.
Lung Cancer, 2016 Aug 28; 99. PMID: 27565919    Free PMC article.
A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling.
Heather L McArthur, Adi Diab, +27 authors, Larry Norton.
Clin Cancer Res, 2016 Nov 05; 22(23). PMID: 27566765    Free PMC article.
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
Jeroen de Filette, Yanina Jansen, +4 authors, Bert Bravenboer.
J Clin Endocrinol Metab, 2016 Nov 05; 101(11). PMID: 27571185    Free PMC article.
Highly Cited.
Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma.
Nathalie Krecké, Anna Zimmer, +3 authors, Claudia Pföhler.
Dermatoendocrinol, 2016 Aug 31; 8(1). PMID: 27574531    Free PMC article.
Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond.
Cristina Migali, Monica Milano, +5 authors, Giuseppe Curigliano.
Ther Adv Med Oncol, 2016 Sep 02; 8(5). PMID: 27583028    Free PMC article.
Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity.
Weiyi Peng, Jodi A McKenzie, Patrick Hwu.
Cancer Discov, 2016 Sep 03; 6(9). PMID: 27587467    Free PMC article.
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.
Maria Secrier, Xiaodun Li, +24 authors, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Consortium.
Nat Genet, 2016 Sep 07; 48(10). PMID: 27595477    Free PMC article.
Highly Cited.
Pembrolizumab for the treatment of advanced melanoma.
Michael C Burns, Aidan O'Donnell, Igor Puzanov.
Expert Opin Orphan Drugs, 2016 Sep 07; 4(8). PMID: 27597930    Free PMC article.
[Immunotherapeutic studies of head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].
C-J Busch, S Laban, R Knecht, T K Hoffmann.
HNO, 2016 Sep 09; 64(10). PMID: 27604282
Combination therapeutics in complex diseases.
Bing He, Cheng Lu, +5 authors, Aiping Lu.
J Cell Mol Med, 2016 Sep 09; 20(12). PMID: 27605177    Free PMC article.
Immunotherapy in human colorectal cancer: Challenges and prospective.
Xuan Sun, Jian Suo, Jun Yan.
World J Gastroenterol, 2016 Sep 09; 22(28). PMID: 27605872    Free PMC article.
Addressing intra-tumoral heterogeneity and therapy resistance.
Brad Rybinski, Kyuson Yun.
Oncotarget, 2016 Sep 10; 7(44). PMID: 27608848    Free PMC article.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Optimal Use of BRAF Targeting Therapy in the Immunotherapy Era.
Kevin Wood, Jason J Luke.
Curr Oncol Rep, 2016 Sep 11; 18(11). PMID: 27613168
Melanoma central nervous system metastases: current approaches, challenges, and opportunities.
Justine V Cohen, Hussain Tawbi, +19 authors, Harriet M Kluger.
Pigment Cell Melanoma Res, 2016 Oct 23; 29(6). PMID: 27615400    Free PMC article.
Wnt signaling in cancer.
T Zhan, N Rindtorff, M Boutros.
Oncogene, 2016 Sep 13; 36(11). PMID: 27617575    Free PMC article.
Highly Cited. Review.
Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response.
Joana Felix, Jérome Lambert, +13 authors, Hélène Moins-Teisserenc.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622012    Free PMC article.
Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
Rikke B Holmgaard, Alexandra Brachfeld, +7 authors, Taha Merghoub.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622016    Free PMC article.
Embracing rejection: Immunologic trends in brain metastasis.
S Harrison Farber, Vadim Tsvankin, +6 authors, Peter E Fecci.
Oncoimmunology, 2016 Sep 14; 5(7). PMID: 27622023    Free PMC article.
Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.
Steve Boudewijns, Rutger H T Koornstra, +8 authors, Winald R Gerritsen.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622070    Free PMC article.
Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction.
Djoke Hendriks, Yuan He, +5 authors, Edwin Bremer.
Oncoimmunology, 2016 Sep 14; 5(8). PMID: 27622071    Free PMC article.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
F Stephen Hodi, Jason Chesney, +18 authors, Michael A Postow.
Lancet Oncol, 2016 Sep 14; 17(11). PMID: 27622997    Free PMC article.
Highly Cited.
Immunotherapy in a rare case of primary pelvic retroperitoneal melanoma.
Maria Monica Talag, Mohamed Alsharedi, Nadim Bou Zgheib, Yehuda Lebowicz.
BMJ Case Rep, 2016 Sep 15; 2016. PMID: 27624447    Free PMC article.
Combination treatment including targeted therapy for advanced hepatocellular carcinoma.
Jianzhen Lin, Liangcai Wu, +8 authors, Haitao Zhao.
Oncotarget, 2016 Sep 15; 7(43). PMID: 27626176    Free PMC article.
The role of dendritic cells in cancer.
Morten Hansen, Mads Hald Andersen.
Semin Immunopathol, 2016 Sep 18; 39(3). PMID: 27638181
Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
Shalin Shah, James E Ward, +3 authors, Jason J Luke.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27638840    Free PMC article.
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, +26 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Sep 21; 35(7). PMID: 27646942    Free PMC article.
Highly Cited.
Immunotherapy for prostate cancer: False promises or true hope?
Brian T Rekoske, Douglas G McNeel.
Cancer, 2016 Sep 21; 122(23). PMID: 27649312    Free PMC article.
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy.
Klaus Okkenhaug, Mariona Graupera, Bart Vanhaesebroeck.
Cancer Discov, 2016 Sep 23; 6(10). PMID: 27655435    Free PMC article.
Highly Cited. Review.
Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.
Yu Mei, Wenya Linda Bi, +11 authors, Ian F Dunn.
Oncotarget, 2016 Sep 23; 7(47). PMID: 27655724    Free PMC article.
Surgical immune interventions for solid malignancies.
Masha Zeltsman, Marissa Mayor, David R Jones, Prasad S Adusumilli.
Am J Surg, 2016 Sep 24; 212(4). PMID: 27659157    Free PMC article.
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma.
Elizabeth I Buchbinder, Anasuya Gunturi, +17 authors, David F McDermott.
J Immunother Cancer, 2016 Sep 24; 4. PMID: 27660706    Free PMC article.
Radiotherapy to Control Limited Melanoma Progression Following Ipilimumab.
Lauren M Kropp, Jennifer F De Los Santos, Svetlana B McKee, Robert M Conry.
J Immunother, 2016 Sep 24; 39(9). PMID: 27662339    Free PMC article.
Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer.
Yeonjoo Choi, Jin Won Kim, +7 authors, Hyung-Ho Kim.
Gastric Cancer, 2016 Sep 26; 20(4). PMID: 27665104
Local delivery of checkpoints antibodies.
Chao Wang, Yanqi Ye, Zhen Gu.
Hum Vaccin Immunother, 2016 Sep 27; 13(1). PMID: 27668759    Free PMC article.
Immunotherapy for Gastroesophageal Cancer.
Emily F Goode, Elizabeth C Smyth.
J Clin Med, 2016 Sep 27; 5(10). PMID: 27669318    Free PMC article.
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Douglas B Johnson, Garrett M Frampton, +24 authors, Christine M Lovly.
Cancer Immunol Res, 2016 Nov 03; 4(11). PMID: 27671167    Free PMC article.
Highly Cited.
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
Shiro Kimbara, Shunsuke Kondo.
World J Gastroenterol, 2016 Sep 28; 22(33). PMID: 27672267    Free PMC article.
The full blood count as a biomarker of outcome and toxicity in ipilimumab-treated cutaneous metastatic melanoma.
Leila Khoja, Eshetu G Atenafu, +6 authors, Anthony M Joshua.
Cancer Med, 2016 Oct 30; 5(10). PMID: 27683208    Free PMC article.
Economic Burden of Toxicities Associated with Treating Metastatic Melanoma in the United States.
S Pinar Bilir, Qiufei Ma, +3 authors, Beth Barber.
Am Health Drug Benefits, 2016 Oct 01; 9(4). PMID: 27688833    Free PMC article.
The cost and value of cancer drugs - are new innovations outpacing our ability to pay?
Daniel A Goldstein, Salomon M Stemmer, Noa Gordon.
Isr J Health Policy Res, 2016 Oct 01; 5. PMID: 27688873    Free PMC article.
Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?
Fabienne McClanahan, Thomas G Sharp, John G Gribben.
Haematologica, 2016 Oct 04; 101(10). PMID: 27694502    Free PMC article.
NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.
Peter E Clark, Philippe E Spiess, +33 authors, Courtney Smith.
J Natl Compr Canc Netw, 2016 Oct 05; 14(10). PMID: 27697976    Free PMC article.
Genomic Approaches to Understanding Response and Resistance to Immunotherapy.
David A Braun, Kelly P Burke, Eliezer M Van Allen.
Clin Cancer Res, 2016 Oct 05; 22(23). PMID: 27698000    Free PMC article.
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities.
Sumit K Subudhi, Ana Aparicio, +14 authors, Padmanee Sharma.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(42). PMID: 27698113    Free PMC article.
Highly Cited.
Current Status and Perspective of Immunotherapy in Gastrointestinal Cancers.
Jung Hoon Kim, Bum Jun Kim, Hyeong Su Kim, Jung Han Kim.
J Cancer, 2016 Oct 05; 7(12). PMID: 27698896    Free PMC article.
Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
Matteo S Carlino, Vito Vanella, +7 authors, Paolo A Ascierto.
Br J Cancer, 2016 Oct 07; 115(11). PMID: 27711085    Free PMC article.
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Ajjai Alva, Gregory A Daniels, +18 authors, Janice P Dutcher.
Cancer Immunol Immunother, 2016 Oct 08; 65(12). PMID: 27714434    Free PMC article.
Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.
Xi Zhang, Yuge Ran, +2 authors, Jinghua Li.
Drug Des Devel Ther, 2016 Oct 13; 10. PMID: 27729774    Free PMC article.
Cancer immunotherapy in patients with preexisting autoimmune disorders.
Marco Donia, Magnus Pedersen, Inge Marie Svane.
Semin Immunopathol, 2016 Oct 13; 39(3). PMID: 27730287
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma.
Nageatte Ibrahim, Elizabeth I Buchbinder, +7 authors, F Stephen Hodi.
Cancer Med, 2016 Oct 18; 5(11). PMID: 27748045    Free PMC article.
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities.
Laura C Cappelli, Ami A Shah, Clifton O Bingham.
RMD Open, 2016 Oct 19; 2(2). PMID: 27752360    Free PMC article.
Nivolumab for melanoma, non-small cell lung cancer.
Aust Prescr, 2016 Oct 21; 39(4). PMID: 27756979    Free PMC article.
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.
Troels Holz Borch, Lotte Engell-Noerregaard, +6 authors, Inge Marie Svane.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757300    Free PMC article.
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma.
E Liniker, A M Menzies, +10 authors, G V Long.
Oncoimmunology, 2016 Oct 21; 5(9). PMID: 27757312    Free PMC article.
Highly Cited.
Pharmacological interventions for melanoma: Comparative analysis using bayesian meta-analysis.
Yang Yang, Jiaomiao Pei, +4 authors, Jianhua Qiu.
Oncotarget, 2016 Oct 21; 7(49). PMID: 27764796    Free PMC article.
Drug Combinations as the New Standard for Melanoma Treatment.
Marta Polkowska, Edyta Czepielewska, Małgorzata Kozłowska-Wojciechowska.
Curr Treat Options Oncol, 2016 Oct 22; 17(12). PMID: 27766547
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.
Kelly D Moynihan, Cary F Opel, +19 authors, Darrell J Irvine.
Nat Med, 2016 Nov 01; 22(12). PMID: 27775706    Free PMC article.
Highly Cited.
Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
E Ilett, T Kottke, +12 authors, R Vile.
Gene Ther, 2016 Oct 26; 24(1). PMID: 27779616    Free PMC article.
Aptamers: A New Technological Platform in Cancer Immunotherapy.
Fernando Pastor.
Pharmaceuticals (Basel), 2016 Oct 27; 9(4). PMID: 27783034    Free PMC article.
Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes.
Marlana Orloff.
Oncolytic Virother, 2016 Oct 28; 5. PMID: 27785448    Free PMC article.
Approaches to modernize the combination drug development paradigm.
Daphne Day, Lillian L Siu.
Genome Med, 2016 Oct 30; 8(1). PMID: 27793177    Free PMC article.
Checkpoint inhibitors in lung cancer: latest developments and clinical potential.
Gustavo Schvartsman, Renata Ferrarotto, Erminia Massarelli.
Ther Adv Med Oncol, 2016 Nov 02; 8(6). PMID: 27800034    Free PMC article.
Patterns and Timing of Initial Relapse in Pathologic Stage II Melanoma Patients.
Ann Y Lee, Nicolas Droppelmann, +5 authors, Daniel G Coit.
Ann Surg Oncol, 2016 Nov 03; 24(4). PMID: 27804026    Free PMC article.
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
Douglas B Johnson, Justin M Balko, +29 authors, Javid J Moslehi.
N Engl J Med, 2016 Nov 03; 375(18). PMID: 27806233    Free PMC article.
Highly Cited.
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Andrea Botticelli, Ilaria Zizzari, +6 authors, Paolo Marchetti.
Oncotarget, 2016 Nov 03; 8(5). PMID: 27806346    Free PMC article.
Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?
Robert O Dillman.
Hum Vaccin Immunother, 2016 Nov 04; 13(3). PMID: 27808593    Free PMC article.
Eph Receptor Tyrosine Kinases in Tumor Immunity.
Eileen Shiuan, Jin Chen.
Cancer Res, 2016 Nov 05; 76(22). PMID: 27811149    Free PMC article.
The Treatment of Melanoma Brain Metastases.
Nour Kibbi, Harriet Kluger.
Curr Oncol Rep, 2016 Nov 09; 18(12). PMID: 27822695
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
Hazem E Ghoneim, Anthony E Zamora, Paul G Thomas, Ben A Youngblood.
Trends Mol Med, 2016 Nov 09; 22(12). PMID: 27825667    Free PMC article.
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.
Olivier De Henau, Matthew Rausch, +21 authors, Taha Merghoub.
Nature, 2016 Nov 10; 539(7629). PMID: 27828943    Free PMC article.
Highly Cited.
Combinatorial immunotherapy for melanoma.
D D George, V A Armenio, S C Katz.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834353
Gene-expression profiling to predict responsiveness to immunotherapy.
N B Jamieson, A V Maker.
Cancer Gene Ther, 2016 Nov 12; 24(3). PMID: 27834354    Free PMC article.
Making urothelial carcinomas less immune to immunotherapy.
Jorge D Ramos, Evan Y Yu.
Urol Oncol, 2016 Nov 12; 34(12). PMID: 27836245    Free PMC article.
Checkpoint Proteins in Pediatric Brain and Extracranial Solid Tumors: Opportunities for Immunotherapy.
Eric K Ring, James M Markert, G Yancey Gillespie, Gregory K Friedman.
Clin Cancer Res, 2016 Nov 12; 23(2). PMID: 27836863    Free PMC article.
Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma.
Stefani Spranger, Jason J Luke, +6 authors, Thomas F Gajewski.
Proc Natl Acad Sci U S A, 2016 Nov 12; 113(48). PMID: 27837020    Free PMC article.
Highly Cited.
Basis for molecular diagnostics and immunotherapy for esophageal cancer.
Joe Abdo, Devendra K Agrawal, Sumeet K Mittal.
Expert Rev Anticancer Ther, 2016 Nov 15; 17(1). PMID: 27838937    Free PMC article.
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study.
R Gutzmer, L Rivoltini, +22 authors, F F Lehmann.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843625    Free PMC article.
Recent advances in the biology of human circulating tumour cells and metastasis.
Sofia Gkountela, Barbara Szczerba, Cinzia Donato, Nicola Aceto.
ESMO Open, 2016 Nov 16; 1(4). PMID: 27843628    Free PMC article.
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis.
BaSang CiRen, Xinhua Wang, Ziwen Long.
Oncotarget, 2016 Nov 16; 7(49). PMID: 27845904    Free PMC article.
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Paolo A Ascierto, Sanjiv Agarwala, +33 authors, Magdalena Thurin.
J Transl Med, 2016 Nov 17; 14(1). PMID: 27846884    Free PMC article.
Preclinical Advances with Multiphoton Microscopy in Live Imaging of Skin Cancers.
Thomas Yang Sun, Ann M Haberman, Valentina Greco.
J Invest Dermatol, 2016 Nov 17; 137(2). PMID: 27847119    Free PMC article.
Systemic Therapies for Late-stage Melanoma.
Peter W Hashim, Philip Friedlander, Gary Goldenberg.
J Clin Aesthet Dermatol, 2016 Nov 17; 9(10). PMID: 27847547    Free PMC article.
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Maarten Swart, Inge Verbrugge, Joost B Beltman.
Front Oncol, 2016 Nov 17; 6. PMID: 27847783    Free PMC article.
Highly Cited. Review.
Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Ricardo Costa, Benedito A Carneiro, +6 authors, Francis J Giles.
Oncotarget, 2016 Nov 17; 8(5). PMID: 27852042    Free PMC article.
Systematic Review.
Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades.
Asha M Das, Mario Pescatori, +5 authors, Timo L M Ten Hagen.
Oncoimmunology, 2016 Nov 18; 5(10). PMID: 27853641    Free PMC article.
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Adil I Daud, Jedd D Wolchok, +21 authors, Omid Hamid.
J Clin Oncol, 2016 Nov 20; 34(34). PMID: 27863197    Free PMC article.
Highly Cited.
Challenges in the use of immunotherapy in metastatic melanoma.
Ashley Tran, Shayna Sarosiek, Naomi Y Ko.
BMJ Case Rep, 2016 Nov 20; 2016. PMID: 27864299    Free PMC article.
Immunotherapy in small-cell lung cancer: at what point are we?
Antonio Rossi.
Ann Transl Med, 2016 Nov 22; 4(Suppl 1). PMID: 27867973    Free PMC article.
Immune checkpoint inhibition in patients with brain metastases.
Tanner Johanns, Saiama N Waqar, Daniel Morgensztern.
Ann Transl Med, 2016 Nov 22; 4(Suppl 1). PMID: 27867977    Free PMC article.
Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.
Michal Bassani-Sternberg, Eva Bräunlein, +16 authors, Angela M Krackhardt.
Nat Commun, 2016 Nov 22; 7. PMID: 27869121    Free PMC article.
Highly Cited.
Potential applications of nanoparticles in cancer immunotherapy.
Yimei Jia, Abdelwahab Omri, Lakshmi Krishnan, Michael J McCluskie.
Hum Vaccin Immunother, 2016 Nov 22; 13(1). PMID: 27870598    Free PMC article.
Metastatic Merkel cell carcinoma response to nivolumab.
Frances M Walocko, Benjamin Y Scheier, +2 authors, Christopher D Lao.
J Immunother Cancer, 2016 Nov 24; 4. PMID: 27879975    Free PMC article.
Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.
Jasna Aleksova, Peter K H Lau, Georgia Soldatos, Grant McArthur.
BMJ Case Rep, 2016 Nov 25; 2016. PMID: 27881588    Free PMC article.
Comparison of exome-based HLA class I genotyping tools: identification of platform-specific genotyping errors.
Kazuma Kiyotani, Tu H Mai, Yusuke Nakamura.
J Hum Genet, 2016 Nov 25; 62(3). PMID: 27881843    Free PMC article.
Ipilimumab: from preclinical development to future clinical perspectives in melanoma.
Paul Letendre, Varun Monga, Mohammed Milhem, Yousef Zakharia.
Future Oncol, 2016 Nov 25; 13(7). PMID: 27882779    Free PMC article.
The emerging role of immune checkpoint inhibition in malignant lymphoma.
Ida Hude, Stephanie Sasse, Andreas Engert, Paul J Bröckelmann.
Haematologica, 2016 Nov 26; 102(1). PMID: 27884973    Free PMC article.
Advances in Cancer Immunotherapy in Solid Tumors.
Smitha Menon, Sarah Shin, Grace Dy.
Cancers (Basel), 2016 Nov 26; 8(12). PMID: 27886124    Free PMC article.
Highly Cited. Review.
Immune-Related Adverse Effects of Cancer Immunotherapy- Implications for Rheumatology.
Laura C Cappelli, Ami A Shah, Clifton O Bingham.
Rheum Dis Clin North Am, 2016 Nov 29; 43(1). PMID: 27890174    Free PMC article.
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
Brian I Rini, David F McDermott, +17 authors, Michael B Atkins.
J Immunother Cancer, 2016 Nov 29; 4. PMID: 27891227    Free PMC article.
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Kevin J Harrington, Robert Hi Andtbacka, +4 authors, Howard L Kaufman.
Onco Targets Ther, 2016 Nov 30; 9. PMID: 27895500    Free PMC article.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
Giuseppe V Masucci, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 30; 4. PMID: 27895917    Free PMC article.
Highly Cited. Review.
Recent Advances in Immunotherapy in Metastatic NSCLC.
Pranshu Bansal, Diaa Osman, +2 authors, Yanis Boumber.
Front Oncol, 2016 Nov 30; 6. PMID: 27896216    Free PMC article.
What does PD-L1 positive or negative mean?
Antoni Ribas, Siwen Hu-Lieskovan.
J Exp Med, 2016 Dec 03; 213(13). PMID: 27903604    Free PMC article.
Highly Cited. Review.
The role of immune checkpoint inhibition in the treatment of ovarian cancer.
Stéphanie L Gaillard, Angeles A Secord, Bradley Monk.
Gynecol Oncol Res Pract, 2016 Dec 03; 3. PMID: 27904752    Free PMC article.
Improved survival and complete response rates in patients with advanced melanoma treated with concurrent ipilimumab and radiotherapy versus ipilimumab alone.
Kristian M Koller, Heath B Mackley, +9 authors, Joseph J Drabick.
Cancer Biol Ther, 2016 Dec 03; 18(1). PMID: 27905824    Free PMC article.
Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.
Corinne A Levingston, M Rita I Young.
Int J Cancer, 2016 Dec 04; 140(7). PMID: 27914100    Free PMC article.
Sequential Therapy with Nivolumab Followed by Ipilimumab Induces Complete Response in Metastatic Melanoma of the Lung but with Severe Hepatotoxicities.
Sadanori Furudate, Taku Fujimura, +3 authors, Setsuya Aiba.
Case Rep Oncol, 2016 Dec 07; 9(3). PMID: 27920696    Free PMC article.
Diversity and collaboration for effective immunotherapy.
Karolina Palucka, Jacques Banchereau.
Nat Med, 2016 Dec 07; 22(12). PMID: 27923023
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Geoffrey T Gibney, Louis M Weiner, Michael B Atkins.
Lancet Oncol, 2016 Dec 08; 17(12). PMID: 27924752    Free PMC article.
Highly Cited. Review.
Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.
Noboru Yamamoto, Hiroshi Nokihara, +7 authors, Tomohide Tamura.
Invest New Drugs, 2016 Dec 09; 35(2). PMID: 27928714    Free PMC article.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D Hellmann, Naiyer A Rizvi, +14 authors, Scott J Antonia.
Lancet Oncol, 2016 Dec 10; 18(1). PMID: 27932067    Free PMC article.
Highly Cited.
Immunotherapy in the Precision Medicine Era: Melanoma and Beyond.
Mack Y Su, David E Fisher.
PLoS Med, 2016 Dec 14; 13(12). PMID: 27959922    Free PMC article.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Nina Deppisch, Peter Ruf, +2 authors, Ralph Mocikat.
Oncotarget, 2016 Dec 15; 8(3). PMID: 27966460    Free PMC article.
Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.
M Kudo.
Liver Cancer, 2016 Dec 21; 6(1). PMID: 27995082    Free PMC article.
Immuno-Oncology: The Third Paradigm in Early Drug Development.
Juan Martin-Liberal, Cinta Hierro, Maria Ochoa de Olza, Jordi Rodon.
Target Oncol, 2016 Dec 21; 12(2). PMID: 27995439
Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature.
Laura C Cappelli, Anna Kristina Gutierrez, Clifton O Bingham, Ami A Shah.
Arthritis Care Res (Hoboken), 2016 Dec 21; 69(11). PMID: 27998041    Free PMC article.
Highly Cited. Systematic Review.
Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.
Marcel A Deken, Ji-Ying Song, +4 authors, Christian U Blank.
Int J Mol Sci, 2016 Dec 22; 17(12). PMID: 27999416    Free PMC article.
Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.
Omar Hasan Ali, Stefan Diem, +6 authors, Lukas Flatz.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999741    Free PMC article.
Immune response and long-term clinical outcome in advanced melanoma patients vaccinated with tumor-mRNA-transfected dendritic cells.
Jon Amund Kyte, Steinar Aamdal, +6 authors, Gunnar Kvalheim.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999747    Free PMC article.
Responses to immune checkpoint inhibitors in nonagenarians.
Romany A N Johnpulle, Robert M Conry, +2 authors, Douglas B Johnson.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999751    Free PMC article.
PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.
Joseph M Obeid, Gulsun Erdag, +5 authors, Craig L Slingluff.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999753    Free PMC article.
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Xinqi Wu, Anita Giobbie-Hurder, +15 authors, F Stephen Hodi.
Cancer Immunol Res, 2016 Dec 23; 5(1). PMID: 28003187    Free PMC article.
Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?
Valérie Dutoit, Denis Migliorini, Pierre-Yves Dietrich, Paul R Walker.
Front Oncol, 2016 Dec 23; 6. PMID: 28003994    Free PMC article.
Autologous reconstitution of human cancer and immune system in vivo.
Juan Fu, Rupashree Sen, +6 authors, Young J Kim.
Oncotarget, 2016 Dec 23; 8(2). PMID: 28008146    Free PMC article.
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation.
Kankana Bardhan, Theodora Anagnostou, Vassiliki A Boussiotis.
Front Immunol, 2016 Dec 27; 7. PMID: 28018338    Free PMC article.
Highly Cited. Review.
PD-L1 Is Not Constitutively Expressed on Tasmanian Devil Facial Tumor Cells but Is Strongly Upregulated in Response to IFN-γ and Can Be Expressed in the Tumor Microenvironment.
Andrew S Flies, A Bruce Lyons, +5 authors, John D Hayball.
Front Immunol, 2016 Dec 27; 7. PMID: 28018348    Free PMC article.
Driving gene-engineered T cell immunotherapy of cancer.
Laura A Johnson, Carl H June.
Cell Res, 2016 Dec 28; 27(1). PMID: 28025979    Free PMC article.
Highly Cited. Review.
Long-term outcomes after carbon-ion radiotherapy for oral mucosal malignant melanoma.
Kensuke Naganawa, Masashi Koto, +6 authors, Organizing Committee for the Working Group for Head-and-Neck Cancer.
J Radiat Res, 2016 Dec 29; 58(4). PMID: 28028129    Free PMC article.
Update on immune checkpoint inhibitors in gynecological cancers.
Valerie Heong, Natalie Ngoi, David Shao Peng Tan.
J Gynecol Oncol, 2016 Dec 29; 28(2). PMID: 28028993    Free PMC article.
Radiotherapy and immune checkpoint blockades: a snapshot in 2016.
Taeryool Koo, In Ah Kim.
Radiat Oncol J, 2016 Dec 30; 34(4). PMID: 28030901    Free PMC article.
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire.
David Y Oh, Jason Cham, +5 authors, Lawrence Fong.
Cancer Res, 2016 Dec 30; 77(6). PMID: 28031229    Free PMC article.
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.
Andrew S Brohl, Nikhil I Khushalani, +5 authors, Jeffrey S Weber.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031816    Free PMC article.
Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature.
Joshua E Reuss, Paul R Kunk, +3 authors, Elizabeth M Gaughan.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031822    Free PMC article.
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
Claire F Friedman, Varina Clark, +8 authors, Michael A Postow.
J Natl Cancer Inst, 2017 Jan 04; 109(4). PMID: 28040701    Free PMC article.
A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet.
Gabriele D'Errico, Heather L Machado, Bruno Sainz.
Clin Transl Med, 2017 Jan 05; 6(1). PMID: 28050779    Free PMC article.
Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Sandra P D'Angelo, James Larkin, +19 authors, Jedd D Wolchok.
J Clin Oncol, 2017 Jan 06; 35(2). PMID: 28056206    Free PMC article.
Highly Cited.
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.
W Joost Lesterhuis, Anthony Bosco, +3 authors, Richard A Lake.
Nat Rev Drug Discov, 2017 Jan 07; 16(4). PMID: 28057932
Highly Cited. Review.
Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer.
Emeka K Enwere, Elizabeth N Kornaga, +8 authors, Corinne M Doll.
Mod Pathol, 2017 Jan 07; 30(4). PMID: 28059093
Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
Yusuke Inoue, Katsuhiro Yoshimura, +10 authors, Haruhiko Sugimura.
Oncotarget, 2017 Jan 07; 8(5). PMID: 28060732    Free PMC article.
Highly Cited.
Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects.
Kenneth G Liu, Sorab Gupta, Sanjay Goel.
Oncotarget, 2017 Jan 07; 8(10). PMID: 28061473    Free PMC article.
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger.
Cell Commun Signal, 2017 Jan 12; 15(1). PMID: 28073373    Free PMC article.
Highly Cited. Review.
Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review.
Aurélien Simon, Hampig Raphael Kourie, Joseph Kerger.
Chin J Cancer, 2017 Jan 15; 36(1). PMID: 28086948    Free PMC article.
Nivolumab in Metastatic Non-Small Cell Lung Cancer.
Andrea Deel.
J Adv Pract Oncol, 2017 Jan 17; 7(2). PMID: 28090370    Free PMC article.
Update on advanced melanoma treatments: small molecule targeted therapy, immunotherapy, and future combination therapies.
Andrew Kwong, Martina Sanlorenzo, Klemens Rappersberger, Igor Vujic.
Wien Med Wochenschr, 2017 Jan 17; 169(13-14). PMID: 28091975
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?
Franck Carbonnel, Emilie Soularue, +4 authors, Caroline Robert.
Semin Immunopathol, 2017 Jan 18; 39(3). PMID: 28093620
Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu.
Nat Rev Clin Oncol, 2017 Jan 18; 14(6). PMID: 28094262
Highly Cited. Review.
Synthetic lethality: emerging targets and opportunities in melanoma.
Nicola Thompson, David J Adams, Marco Ranzani.
Pigment Cell Melanoma Res, 2017 Jan 18; 30(2). PMID: 28097822    Free PMC article.
Elements of cancer immunity and the cancer-immune set point.
Daniel S Chen, Ira Mellman.
Nature, 2017 Jan 20; 541(7637). PMID: 28102259
Highly Cited. Review.
Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
Adil Daud, Harriet M Kluger, +6 authors, Geoffrey I Shapiro.
Br J Cancer, 2017 Jan 20; 116(4). PMID: 28103611    Free PMC article.
Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
Julia Escandon, Stephanie Peacock, +3 authors, Jose Lutzky.
J Immunother Cancer, 2017 Jan 21; 5. PMID: 28105370    Free PMC article.
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
David J Byun, Jedd D Wolchok, Lynne M Rosenberg, Monica Girotra.
Nat Rev Endocrinol, 2017 Jan 21; 13(4). PMID: 28106152    Free PMC article.
Highly Cited. Review.
From the Guest Editors: Recent Advances and Evolving Challenges in Treating Unresectable Melanoma.
Sarah A Weiss, Harriet M Kluger.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114248    Free PMC article.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114250    Free PMC article.
Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy in Need of Further Investigation.
Freddy E Escorcia, Michael A Postow, Christopher A Barker.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114252    Free PMC article.
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
Marcel A Deken, Jules Gadiot, +13 authors, Christian U Blank.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123875    Free PMC article.
Highly Cited.
T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy.
Jon Amund Kyte, Gustav Gaudernack, +7 authors, Martin Pule.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123886    Free PMC article.
Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.
V Damuzzo, S Solito, +6 authors, S Mandruzzato.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123888    Free PMC article.
Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy.
Henoch S Hong, Sven D Koch, +9 authors, James M Billingsley.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123889    Free PMC article.
PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.
T Jelinek, R Hajek.
Oncoimmunology, 2017 Jan 27; 5(12). PMID: 28123899    Free PMC article.
Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors.
Peyton Cramer, Robert S Bresalier.
Curr Gastroenterol Rep, 2017 Jan 27; 19(1). PMID: 28124291
PD-L1 Expression in Pancreatic Cancer.
Lei Zheng.
J Natl Cancer Inst, 2017 Jan 31; 109(6). PMID: 28131993    Free PMC article.
Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal.
Cancers (Basel), 2017 Jan 31; 9(2). PMID: 28134806    Free PMC article.
Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients.
Tristen S Park, Giao Q Phan, +7 authors, Richard M Sherry.
Ann Surg Oncol, 2017 Feb 02; 24(4). PMID: 28144760    Free PMC article.
The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors.
Matthew R Farren, Rebecca C Hennessey, +10 authors, Gregory B Lesinski.
Mol Cancer Ther, 2017 Feb 06; 16(3). PMID: 28148715    Free PMC article.
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.
Hongjuan Zhao, Shoucheng Ning, +4 authors, Donna M Peehl.
Clin Epigenetics, 2017 Feb 06; 9. PMID: 28149332    Free PMC article.
Acquired resistance mechanisms to immunotherapy.
Teresa Amaral, Claus Garbe.
Ann Transl Med, 2017 Feb 06; 4(24). PMID: 28149908    Free PMC article.
Immune Checkpoint Blockade and Hematopoietic Stem Cell Transplant.
Reid W Merryman, Philippe Armand.
Curr Hematol Malig Rep, 2017 Feb 06; 12(1). PMID: 28155012
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.
Kilian Wistuba-Hamprecht, Alexander Martens, +18 authors, Benjamin Weide.
Eur J Cancer, 2017 Feb 09; 73. PMID: 28167454    Free PMC article.
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
A K S Salama, S J Moschos.
Ann Oncol, 2017 Feb 09; 28(1). PMID: 28177433    Free PMC article.
Non-tumor cell IDO1 predominantly contributes to enzyme activity and response to CTLA-4/PD-L1 inhibition in mouse glioblastoma.
Lijie Zhai, Erik Ladomersky, +8 authors, Derek A Wainwright.
Brain Behav Immun, 2017 Feb 10; 62. PMID: 28179106    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Renal complications of immune checkpoint blockade.
Naoka Murakami, Shveta Motwani, Leonardo V Riella.
Curr Probl Cancer, 2017 Feb 13; 41(2). PMID: 28189263    Free PMC article.
PD-L1 up-regulation in melanoma increases disease aggressiveness and is mediated through miR-17-5p.
Valentina Audrito, Sara Serra, +14 authors, Silvia Deaglio.
Oncotarget, 2017 Feb 16; 8(9). PMID: 28199980    Free PMC article.
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.
Viktoria Bergqvist, Erik Hertervig, +5 authors, Jan Marsal.
Cancer Immunol Immunother, 2017 Feb 17; 66(5). PMID: 28204866    Free PMC article.
Highly Cited.
Cardiovascular Toxicities Associated with Cancer Immunotherapies.
Daniel Y Wang, Gosife Donald Okoye, +2 authors, Javid J Moslehi.
Curr Cardiol Rep, 2017 Feb 22; 19(3). PMID: 28220466
Highly Cited. Review.
Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.
Christine G Kohn, Simon B Zeichner, +3 authors, Christopher R Flowers.
J Clin Oncol, 2017 Feb 22; 35(11). PMID: 28221865    Free PMC article.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma.
Hani M Babiker, Irbaz Bin Riaz, Muhammad Husnain, Mitesh J Borad.
Oncolytic Virother, 2017 Feb 23; 6. PMID: 28224120    Free PMC article.
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy.
Vivek Kumar, Neha Chaudhary, +3 authors, Abhinav B Chandra.
Front Pharmacol, 2017 Feb 24; 8. PMID: 28228726    Free PMC article.
Highly Cited. Review.
Immune Checkpoint Blockade Biology in Mouse Models of Glioblastoma.
Alan T Yeo, Alain Charest.
J Cell Biochem, 2017 Feb 24; 118(9). PMID: 28230277    Free PMC article.
COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Gerardo Botti, Federica Fratangelo, +15 authors, Giosuè Scognamiglio.
J Transl Med, 2017 Feb 25; 15(1). PMID: 28231855    Free PMC article.
Targeting neoantigens to augment antitumour immunity.
Mark Yarchoan, Burles A Johnson, +2 authors, Elizabeth M Jaffee.
Nat Rev Cancer, 2017 Feb 25; 17(4). PMID: 28233802    Free PMC article.
Highly Cited. Review.
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy.
Kevin G Shim, Shane Zaidi, +8 authors, Richard G Vile.
Mol Ther, 2017 Feb 27; 25(4). PMID: 28237836    Free PMC article.
Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.
Reinhard Dummer, Christoph Hoeller, Isabella Pezzani Gruter, Olivier Michielin.
Cancer Immunol Immunother, 2017 Feb 27; 66(6). PMID: 28238174    Free PMC article.
Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Eileen Shiuan, Kathryn E Beckermann, +11 authors, Douglas Johnson.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239462    Free PMC article.
Nivolumab induced myxedema crisis.
Uqba Khan, Humaira Rizvi, +2 authors, Tarik Hadid.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239466    Free PMC article.
Combination immunotherapy: a road map.
Patrick A Ott, F Stephen Hodi, +2 authors, Jedd D Wolchok.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239469    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitors in challenging populations.
Douglas B Johnson, Ryan J Sullivan, Alexander M Menzies.
Cancer, 2017 Feb 28; 123(11). PMID: 28241095    Free PMC article.
Highly Cited. Review.
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma.
Wencheng Zhang, Qingsong Pang, +7 authors, Zefen Xiao.
Onco Targets Ther, 2017 Mar 01; 10. PMID: 28243112    Free PMC article.
First-line treatment of metastatic melanoma: role of nivolumab.
Jeremy Force, April Ks Salama.
Immunotargets Ther, 2017 Mar 01; 6. PMID: 28243579    Free PMC article.
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.
Guillermo De Velasco, Youjin Je, +8 authors, Toni K Choueiri.
Cancer Immunol Res, 2017 Mar 02; 5(4). PMID: 28246107    Free PMC article.
Highly Cited.
From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis.
Melissa Bersanelli, Sebastiano Buti.
World J Clin Oncol, 2017 Mar 02; 8(1). PMID: 28246584    Free PMC article.
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance.
Whijae Roh, Pei-Ling Chen, +37 authors, P Andrew Futreal.
Sci Transl Med, 2017 Mar 03; 9(379). PMID: 28251903    Free PMC article.
Highly Cited.
Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale.
Jaya M Satagopan, Alexia Iasonos.
Contemp Clin Trials, 2017 Mar 04; 63. PMID: 28254404    Free PMC article.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases.
Giuseppe Minniti, Sergio Paolini, +6 authors, Mattia Osti.
J Neurooncol, 2017 Mar 06; 132(3). PMID: 28260130
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.
Liting Guo, Haijun Zhang, Baoan Chen.
J Cancer, 2017 Mar 07; 8(3). PMID: 28261342    Free PMC article.
In Situ Activation of Pituitary-Infiltrating T Lymphocytes in Autoimmune Hypophysitis.
Han-Huei Lin, Angelika Gutenberg, +7 authors, Shey-Cherng Tzou.
Sci Rep, 2017 Mar 07; 7. PMID: 28262761    Free PMC article.
The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology.
Akinori Kawakami, David E Fisher.
Lab Invest, 2017 Mar 07; 97(6). PMID: 28263292
Precision medicine driven by cancer systems biology.
Fabian V Filipp.
Cancer Metastasis Rev, 2017 Mar 08; 36(1). PMID: 28265786    Free PMC article.
Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer.
Shigehiro Koganemaru, Naoko Inoshita, +13 authors, Toshimi Takano.
Cancer Sci, 2017 Mar 08; 108(5). PMID: 28267224    Free PMC article.
Standard of care in immunotherapy trials: Challenges and considerations.
Gareth Rivalland, Andrew M Scott, Thomas John.
Hum Vaccin Immunother, 2017 Mar 08; 13(9). PMID: 28267397    Free PMC article.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.
Jiaying Wu, Dongsheng Hong, +2 authors, Jing Miao.
Sci Rep, 2017 Mar 09; 7. PMID: 28272463    Free PMC article.
PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes.
Yayi He, Leslie Rozeboom, +5 authors, Fred R Hirsch.
Med Sci Monit, 2017 Mar 10; 23. PMID: 28275222    Free PMC article.
Digoxin Plus Trametinib Therapy Achieves Disease Control in BRAF Wild-Type Metastatic Melanoma Patients.
Arthur E Frankel, Ugur Eskiocak, +5 authors, Sean J Morrison.
Neoplasia, 2017 Mar 10; 19(4). PMID: 28278423    Free PMC article.
Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?
Xiangyi Kong, Yanguo Kong.
Onco Targets Ther, 2017 Mar 11; 10. PMID: 28280368    Free PMC article.
Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.
Manohan Sinnadurai, Kerrie L McDonald.
J Neurooncol, 2017 Mar 16; 132(3). PMID: 28293764
Advances in Immunotherapy for Glioblastoma Multiforme.
Boyuan Huang, Hongbo Zhang, +4 authors, Xiaoxing Xiong.
J Immunol Res, 2017 Mar 17; 2017. PMID: 28299344    Free PMC article.
TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.
Wenwen Du, Min Yang, +5 authors, Binfeng Lu.
Int J Mol Sci, 2017 Mar 17; 18(3). PMID: 28300768    Free PMC article.
[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
A Neubauer.
Internist (Berl), 2017 Mar 18; 58(4). PMID: 28303311
Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions.
Hussein Merza, Marijo Bilusic.
Curr Oncol Rep, 2017 Mar 18; 19(4). PMID: 28303494
PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8+ tumor-infiltrating lymphocytes: highly sensitive detection using phosphor-integrated dot staining.
So Yamaki, Hiroaki Yanagimoto, +2 authors, Masanori Kon.
Int J Clin Oncol, 2017 Mar 21; 22(4). PMID: 28314962    Free PMC article.
Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Nigel Fleeman, Adrian Bagust, +8 authors, Miranda Payne.
Pharmacoeconomics, 2017 Mar 21; 35(10). PMID: 28316007
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.
Jason Lohmueller, Olivera J Finn.
Pharmacol Ther, 2017 Mar 23; 178. PMID: 28322974    Free PMC article.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Randy F Sweis, Jason J Luke.
Pharmacol Res, 2017 Mar 23; 120. PMID: 28323141    Free PMC article.
Diagnosis and Treatment of Kaposi Sarcoma.
Johann W Schneider, Dirk P Dittmer.
Am J Clin Dermatol, 2017 Mar 23; 18(4). PMID: 28324233    Free PMC article.
Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
Keisuke Imafuku, Koji Yoshino, +3 authors, Hiroo Hata.
Br J Cancer, 2017 Mar 23; 116(8). PMID: 28324884    Free PMC article.
Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response.
Laurence P Diggs, Eddy C Hsueh.
Biomark Res, 2017 Mar 24; 5. PMID: 28331612    Free PMC article.
Highly Cited. Review.
Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study.
Naoya Yamazaki, Yoshio Kiyohara, +7 authors, Hironobu Minami.
Cancer Sci, 2017 Mar 28; 108(6). PMID: 28342215    Free PMC article.
Development of CAR T cells designed to improve antitumor efficacy and safety.
Janneke E Jaspers, Renier J Brentjens.
Pharmacol Ther, 2017 Mar 28; 178. PMID: 28342824    Free PMC article.
An Anti-Programmed Death-1 Antibody (αPD-1) Fusion Protein That Self-Assembles into a Multivalent and Functional αPD-1 Nanoparticle.
Peng Zhao, Djordje Atanackovic, +3 authors, Mingnan Chen.
Mol Pharm, 2017 Mar 28; 14(5). PMID: 28343398    Free PMC article.
Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.
Eva M Putz, Camille Guillerey, +7 authors, Mark J Smyth.
Oncoimmunology, 2017 Mar 28; 6(2). PMID: 28344878    Free PMC article.
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.
Riikka Havunen, Mikko Siurala, +10 authors, Akseli Hemminki.
Mol Ther Oncolytics, 2017 Mar 28; 4. PMID: 28345026    Free PMC article.
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts.
Dietrich A Ruess, Kivanc Görgülü, Sonja M Wörmann, Hana Algül.
Drugs Aging, 2017 Mar 30; 34(5). PMID: 28349415
Molecular genetic and immunotherapeutic targets in metastatic melanoma.
C Melis, A Rogiers, O Bechter, Joost J van den Oord.
Virchows Arch, 2017 Mar 31; 471(2). PMID: 28357489
ATVB Distinguished Scientist Award: How Costimulatory and Coinhibitory Pathways Shape Atherosclerosis.
Klaus Ley, Norbert Gerdes, Holger Winkels.
Arterioscler Thromb Vasc Biol, 2017 Apr 01; 37(5). PMID: 28360089    Free PMC article.
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Rakesh R Ramjiawan, Arjan W Griffioen, Dan G Duda.
Angiogenesis, 2017 Apr 01; 20(2). PMID: 28361267    Free PMC article.
Highly Cited. Review.
Targeted Therapies for Melanoma Brain Metastases.
Anna S Berghoff, Matthias Preusser.
Curr Treat Options Neurol, 2017 Apr 05; 19(4). PMID: 28374234    Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
[Stable disease or complete response? : A critical evaluation of the radiologic response to immune checkpoint blockade in advanced melanoma].
J K Tietze, M Heppt, +3 authors, C Berking.
Hautarzt, 2017 Apr 07; 68(8). PMID: 28382381
Association of Surgical Treatment, Systemic Therapy, and Survival in Patients With Abdominal Visceral Melanoma Metastases, 1965-2014: Relevance of Surgical Cure in the Era of Modern Systemic Therapy.
Gary B Deutsch, Devin C Flaherty, +5 authors, Anton J Bilchik.
JAMA Surg, 2017 Apr 07; 152(7). PMID: 28384791    Free PMC article.
The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy.
Annie N M Wong, Grant A McArthur, Michael S Hofman, Rodney J Hicks.
Eur J Nucl Med Mol Imaging, 2017 Apr 09; 44(Suppl 1). PMID: 28389693
Genetic evolution of uveal melanoma guides the development of an inflammatory microenvironment.
Gülçin Gezgin, Mehmet Dogrusöz, +8 authors, Martine J Jager.
Cancer Immunol Immunother, 2017 Apr 10; 66(7). PMID: 28391358    Free PMC article.
Indicators of responsiveness to immune checkpoint inhibitors.
Bradley D Shields, Fade Mahmoud, +10 authors, Alan J Tackett.
Sci Rep, 2017 Apr 13; 7(1). PMID: 28400597    Free PMC article.
Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma.
Liang Mao, Teng-Fei Fan, +10 authors, Zhi-Jun Sun.
J Cell Mol Med, 2017 Apr 13; 21(9). PMID: 28401653    Free PMC article.
Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Pauline Gravelle, Barbara Burroni, +7 authors, Camille Laurent.
Oncotarget, 2017 Apr 14; 8(27). PMID: 28402953    Free PMC article.
A novel bispecific c-MET/PD-1 antibody with therapeutic potential in solid cancer.
Zu-Jun Sun, Yi Wu, +4 authors, Min Yu.
Oncotarget, 2017 Apr 14; 8(17). PMID: 28404966    Free PMC article.
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.
Ornella Franzese, Francesco Torino, +5 authors, Stefania D'Atri.
Oncotarget, 2017 Apr 14; 8(25). PMID: 28404974    Free PMC article.
Correlation between previous treatment with BRAF inhibitors and clinical response to pembrolizumab in patients with advanced melanoma.
Ester Simeone, Antonio Maria Grimaldi, +8 authors, Paolo Antonio Ascierto.
Oncoimmunology, 2017 Apr 14; 6(3). PMID: 28405510    Free PMC article.
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.
Frank Kroschinsky, Friedrich Stölzel, +5 authors, Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group.
Crit Care, 2017 Apr 15; 21(1). PMID: 28407743    Free PMC article.
Highly Cited. Review.
Targeted therapy for soft tissue sarcomas in adolescents and young adults.
Diana A Steppan, Christine A Pratilas, David M Loeb.
Adolesc Health Med Ther, 2017 Apr 15; 8. PMID: 28408855    Free PMC article.
Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.
Katrijn Broos, Marleen Keyaerts, +7 authors, Nick Devoogdt.
Oncotarget, 2017 Apr 15; 8(26). PMID: 28410210    Free PMC article.
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Frederick Arce Vargas, Andrew J S Furness, +29 authors, Sergio A Quezada.
Immunity, 2017 Apr 16; 46(4). PMID: 28410988    Free PMC article.
Highly Cited.
Adjuvant Therapy for Melanoma.
Aya Agha, Ahmad A Tarhini.
Curr Oncol Rep, 2017 Apr 19; 19(5). PMID: 28417343
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
Melita Irving, Romain Vuillefroy de Silly, +2 authors, George Coukos.
Front Immunol, 2017 Apr 20; 8. PMID: 28421069    Free PMC article.
"Targeted" Chemotherapy for Esophageal Cancer.
Joe Abdo, Devendra K Agrawal, Sumeet K Mittal.
Front Oncol, 2017 Apr 20; 7. PMID: 28421164    Free PMC article.
[The pathology of adverse events with immune checkpoint inhibitors].
V H Koelzer, K Glatz, +7 authors, K D Mertz.
Pathologe, 2017 Apr 20; 38(3). PMID: 28421272
Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Richard Linedale, Campbell Schmidt, +4 authors, Graham R Leggatt.
PLoS One, 2017 Apr 20; 12(4). PMID: 28423034    Free PMC article.
Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine.
Tyler Lazaro, Priscilla K Brastianos.
CNS Oncol, 2017 Apr 21; 6(2). PMID: 28425754    Free PMC article.
PD-L1 Expression in Melanoma: A Quantitative Immunohistochemical Antibody Comparison.
Joel C Sunshine, Peter L Nguyen, +10 authors, Janis M Taube.
Clin Cancer Res, 2017 Apr 22; 23(16). PMID: 28428193    Free PMC article.
Highly Cited.
Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.
Luc Cabel, Elika Loir, +6 authors, Karim Fizazi.
J Immunother Cancer, 2017 Apr 22; 5. PMID: 28428880    Free PMC article.
Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.
Kasper F Guldbrandsen, Helle W Hendel, Seppo W Langer, Barbara M Fischer.
Diagnostics (Basel), 2017 Apr 22; 7(2). PMID: 28430133    Free PMC article.
Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma.
Jacek Mackiewicz, Andrzej Mackiewicz.
Contemp Oncol (Pozn), 2017 Apr 25; 21(1). PMID: 28435391    Free PMC article.
Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?
Lih Yin Tan, Carmela Martini, +3 authors, Lisa M Ebert.
Clin Transl Immunology, 2017 Apr 25; 6(3). PMID: 28435677    Free PMC article.
Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study.
Eytan Ben-Ami, Constance M Barysauskas, +15 authors, Suzanne George.
Cancer, 2017 Apr 26; 123(17). PMID: 28440953    Free PMC article.
Highly Cited.
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.
Lars M Wagner, Val R Adams.
Onco Targets Ther, 2017 Apr 27; 10. PMID: 28442918    Free PMC article.
Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.
Alice O Kamphorst, Rathi N Pillai, +16 authors, Suresh S Ramalingam.
Proc Natl Acad Sci U S A, 2017 Apr 28; 114(19). PMID: 28446615    Free PMC article.
Highly Cited.
Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study.
Paola Queirolo, Beatrice Dozin, +28 authors, Maria Pia Pistillo.
Front Immunol, 2017 Apr 28; 8. PMID: 28446908    Free PMC article.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.
P A Ott, S A Piha-Paul, +13 authors, J Bennouna.
Ann Oncol, 2017 Apr 30; 28(5). PMID: 28453692    Free PMC article.
Highly Cited.
Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy.
Hengfeng Yuan, Wen Jiang, +9 authors, Betty Y S Kim.
Nat Nanotechnol, 2017 May 02; 12(8). PMID: 28459470
Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response.
Benjamin M Larimer, Eric Wehrenberg-Klee, +5 authors, Umar Mahmood.
Cancer Res, 2017 May 04; 77(9). PMID: 28461564    Free PMC article.
Highly Cited.
A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
Joao Paulo da Silveira Nogueira Lima, Mina Georgieva, Benjamin Haaland, Gilberto de Lima Lopes.
Cancer Med, 2017 May 04; 6(6). PMID: 28463413    Free PMC article.
Systematic Review.
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, +16 authors, Elise C Kohn.
J Clin Oncol, 2017 May 05; 35(19). PMID: 28471727    Free PMC article.
Highly Cited.
Targeting the programmed cell death 1 pathway in Hodgkin lymphoma: the place of nivolumab.
Nathan D Gay, Craig Y Okada, Andy I Chen, Emma C Scott.
Ther Adv Hematol, 2017 May 06; 8(5). PMID: 28473905    Free PMC article.
Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma.
Allison S Betof, Ryan D Nipp, +7 authors, Ryan J Sullivan.
Oncologist, 2017 May 10; 22(8). PMID: 28476944    Free PMC article.
Locoregional and systemic therapy for hepatocellular carcinoma.
Olumide B Gbolahan, Michael A Schacht, +3 authors, Maximilian Pyko.
J Gastrointest Oncol, 2017 May 10; 8(2). PMID: 28480062    Free PMC article.
A new frontier in treatment of advanced melanoma: Redefining clinical management in the era of immune checkpoint inhibitors.
Oren Levine, Tahira Devji, Feng Xie.
Hum Vaccin Immunother, 2017 May 10; 13(8). PMID: 28481695    Free PMC article.
Checkpoint inhibitors in hematological malignancies.
Chi Young Ok, Ken H Young.
J Hematol Oncol, 2017 May 10; 10(1). PMID: 28482851    Free PMC article.
Highly Cited. Review.
Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer.
Prabhsimranjot Singh, Sudhamshi Toom, Yiwu Huang.
J Hematol Oncol, 2017 May 13; 10(1). PMID: 28494772    Free PMC article.
The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1.
Alexander Sankin, Deepa Narasimhulu, +3 authors, Xingxing Zang.
Urol Oncol, 2017 May 13; 36(10). PMID: 28495553    Free PMC article.
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
James Larkin, Bartosz Chmielowski, +9 authors, David A Reardon.
Oncologist, 2017 May 13; 22(6). PMID: 28495807    Free PMC article.
Highly Cited.
Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies.
Upendra P Hegde, Bijay Mukherji.
Cancer Immunol Immunother, 2017 May 13; 66(9). PMID: 28497159    Free PMC article.
Checkpoint inhibition and melanoma: Considerations in treating the older adult.
Claire F Friedman, Jedd D Wolchok.
J Geriatr Oncol, 2017 May 17; 8(4). PMID: 28506536    Free PMC article.
Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Kimberly M Komatsubara, Richard D Carvajal.
Curr Oncol Rep, 2017 May 17; 19(7). PMID: 28508938
Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.
Fade Mahmoud, Bradley Shields, +5 authors, Alan J Tackett.
Cancer Biol Ther, 2017 May 18; 18(7). PMID: 28513269    Free PMC article.
Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease.
Andrew S Flies, Nicholas B Blackburn, +2 authors, Gregory M Woods.
Front Immunol, 2017 May 19; 8. PMID: 28515726    Free PMC article.
Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
Jessie R Nedrow, Anders Josefsson, +3 authors, George Sgouros.
J Nucl Med, 2017 May 20; 58(10). PMID: 28522738    Free PMC article.
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology.
Eddy W Yue, Richard Sparks, +23 authors, Andrew P Combs.
ACS Med Chem Lett, 2017 May 20; 8(5). PMID: 28523098    Free PMC article.
Highly Cited.
Hallmarks of response to immune checkpoint blockade.
Alexandria P Cogdill, Miles C Andrews, Jennifer A Wargo.
Br J Cancer, 2017 May 20; 117(1). PMID: 28524159    Free PMC article.
Highly Cited. Review.
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
Sagun Parakh, John J Park, +16 authors, Matteo S Carlino.
Br J Cancer, 2017 May 20; 116(12). PMID: 28524161    Free PMC article.
Immunogenomics: using genomics to personalize cancer immunotherapy.
Rance C Siniard, Shuko Harada.
Virchows Arch, 2017 May 22; 471(2). PMID: 28528510
Immunotherapy and radiation therapy for malignant pleural mesothelioma.
Evan W Alley, Sharyn I Katz, Keith A Cengel, Charles B Simone.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529903    Free PMC article.
Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
Anna Oh, Dang M Tran, +4 authors, Leslie Wilson.
J Manag Care Spec Pharm, 2017 May 23; 23(6). PMID: 28530525    Free PMC article.
Combinatorial drug delivery approaches for immunomodulation.
Joshua M Stewart, Benjamin G Keselowsky.
Adv Drug Deliv Rev, 2017 May 24; 114. PMID: 28532690    Free PMC article.
HLA-A24 ligandome analysis of colon and lung cancer cells identifies a novel cancer-testis antigen and a neoantigen that elicits specific and strong CTL responses.
Vitaly Kochin, Takayuki Kanaseki, +11 authors, Toshihiko Torigoe.
Oncoimmunology, 2017 May 24; 6(4). PMID: 28533942    Free PMC article.
Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?
Chethan Ramamurthy, James L Godwin, Hossein Borghaei.
Curr Treat Options Oncol, 2017 May 24; 18(6). PMID: 28534248
Combining drugs and extending treatment - a PFS end point is not sufficient.
Bishal Gyawali, Vinay Prasad.
Nat Rev Clin Oncol, 2017 May 24; 14(9). PMID: 28534528
Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.
Ravi A Madan, James L Gulley.
Nat Rev Urol, 2017 May 24; 14(8). PMID: 28534538    Free PMC article.
Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.
Eiichi Ishikawa, Tetsuya Yamamoto, Akira Matsumura.
Neurol Med Chir (Tokyo), 2017 May 26; 57(7). PMID: 28539528    Free PMC article.
Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
Nalini Marino, Sam Illingworth, +6 authors, Alice C N Brown.
PLoS One, 2017 May 26; 12(5). PMID: 28542292    Free PMC article.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, N-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma.
Carlos A Morales-Betanzos, Hyoungjoo Lee, +4 authors, Daniel C Liebler.
Mol Cell Proteomics, 2017 May 27; 16(10). PMID: 28546465    Free PMC article.
Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.
David A Bond, Lapo Alinari.
J Blood Med, 2017 May 27; 8. PMID: 28546779    Free PMC article.
A reconstructed melanoma data set for evaluating differential treatment benefit according to biomarker subgroups.
Jaya M Satagopan, Alexia Iasonos, Joseph G Kanik.
Data Brief, 2017 Jun 01; 12. PMID: 28560273    Free PMC article.
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.
Jingyu Zhang, Dai Liu, +4 authors, Jennifer D Wu.
Sci Adv, 2017 Jun 01; 3(5). PMID: 28560327    Free PMC article.
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions.
Antje Sucker, Fang Zhao, +20 authors, Annette Paschen.
Nat Commun, 2017 Jun 01; 8. PMID: 28561041    Free PMC article.
Highly Cited.
Accumulation of prohibitin is a common cellular response to different stressing stimuli and protects melanoma cells from ER stress and chemotherapy-induced cell death.
Tharcisio Citrangulo Tortelli, Lyris Martins Franco de Godoy, +6 authors, Roger Chammas.
Oncotarget, 2017 Jun 01; 8(26). PMID: 28562344    Free PMC article.
Spotlight on landmark oncology trials: the latest evidence and novel trial designs.
Helena Earl, Stefano Molica, Piotr Rutkowski.
BMC Med, 2017 Jun 03; 15(1). PMID: 28571584    Free PMC article.
Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.
Corinne A Levingston, M Rita I Young.
Cancers (Basel), 2017 Jun 03; 9(6). PMID: 28574425    Free PMC article.
Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Axel Lechner, Hans Schlößer, +15 authors, Dirk Beutner.
Oncotarget, 2017 Jun 03; 8(27). PMID: 28574843    Free PMC article.
Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade.
Jarushka Naidoo, Laura C Cappelli, +13 authors, Julie R Brahmer.
Oncologist, 2017 Jun 04; 22(6). PMID: 28576858    Free PMC article.
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
Michael A Davies, Philippe Saiag, +17 authors, Georgina V Long.
Lancet Oncol, 2017 Jun 09; 18(7). PMID: 28592387    Free PMC article.
Highly Cited.
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
Emma Nolan, Peter Savas, +13 authors, Geoffrey J Lindeman.
Sci Transl Med, 2017 Jun 09; 9(393). PMID: 28592566    Free PMC article.
Highly Cited.
Transcriptional and epigenetic regulation of T cell hyporesponsiveness.
Renata M Pereira, Patrick G Hogan, Anjana Rao, Gustavo J Martinez.
J Leukoc Biol, 2017 Jun 14; 102(3). PMID: 28606939    Free PMC article.
Pembrolizumab in cervical cancer: latest evidence and clinical usefulness.
Edith Borcoman, Christophe Le Tourneau.
Ther Adv Med Oncol, 2017 Jun 14; 9(6). PMID: 28607581    Free PMC article.
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
C Brüggemann, M C Kirchberger, +14 authors, L Heinzerling.
J Cancer Res Clin Oncol, 2017 Jun 16; 143(10). PMID: 28616701
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.
Jeong A Park, Nai-Kong V Cheung.
Cancer Treat Rev, 2017 Jun 18; 58. PMID: 28622628    Free PMC article.
DNA Damage and Repair Biomarkers of Immunotherapy Response.
Kent W Mouw, Michael S Goldberg, Panagiotis A Konstantinopoulos, Alan D D'Andrea.
Cancer Discov, 2017 Jun 21; 7(7). PMID: 28630051    Free PMC article.
Highly Cited. Review.
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
Michal Šmahel.
Int J Mol Sci, 2017 Jun 22; 18(6). PMID: 28635644    Free PMC article.
Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells.
Uwe Thiel, Sebastian J Schober, +16 authors, Stefan E G Burdach.
Oncoimmunology, 2017 Jun 24; 6(5). PMID: 28638739    Free PMC article.
Safe and effective administration of T-VEC in a patient with heart transplantation and recurrent locally advanced melanoma.
Gustavo Schvartsman, Kristen Perez, +2 authors, Hussein Tawbi.
J Immunother Cancer, 2017 Jun 24; 5. PMID: 28642816    Free PMC article.
Cerebral vasculitis mimicking intracranial metastatic progression of lung cancer during PD-1 blockade.
Heinz Läubli, Jürgen Hench, +5 authors, Frank Stenner-Liewen.
J Immunother Cancer, 2017 Jun 24; 5. PMID: 28642817    Free PMC article.
PD-1 and cancer: molecular mechanisms and polymorphisms.
Arash Salmaninejad, Vahid Khoramshahi, +6 authors, Sayed Mostafa Hosseini.
Immunogenetics, 2017 Jun 24; 70(2). PMID: 28642997
New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.
Prasad S Adusumilli, Edward Cha, +18 authors, Daniel S Chen.
J Immunother Cancer, 2017 Jun 27; 5. PMID: 28649381    Free PMC article.
Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer.
Jeffrey P Solzak, Rutuja V Atale, +4 authors, Milan Radovich.
NPJ Breast Cancer, 2017 Jun 27; 3. PMID: 28649657    Free PMC article.
Health-related quality of life results from the phase III CheckMate 067 study.
Dirk Schadendorf, James Larkin, +20 authors, Georgina V Long.
Eur J Cancer, 2017 Jun 27; 82. PMID: 28651159    Free PMC article.
Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.
Sarah Chuzi, Fabio Tavora, +4 authors, Francis J Giles.
Cancer Manag Res, 2017 Jun 28; 9. PMID: 28652812    Free PMC article.
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Chunyan Hao, Jinhui Tian, +3 authors, Bingdong Zhu.
Medicine (Baltimore), 2017 Jun 29; 96(26). PMID: 28658143    Free PMC article.
Systematic Review.
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
Georgina V Long, Jeffrey S Weber, +12 authors, Jedd D Wolchok.
JAMA Oncol, 2017 Jul 01; 3(11). PMID: 28662232    Free PMC article.
Highly Cited.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.
Mohammad Rashidian, Jessica R Ingram, +11 authors, Hidde L Ploegh.
J Exp Med, 2017 Jul 02; 214(8). PMID: 28666979    Free PMC article.
Highly Cited.
Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.
James Larkin, David Minor, +20 authors, Jeffrey Weber.
J Clin Oncol, 2017 Jul 04; 36(4). PMID: 28671856    Free PMC article.
Highly Cited.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Casey R Ager, Matthew J Reilley, +3 authors, Michael A Curran.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674082    Free PMC article.
Highly Cited.
Combining Local Immunotoxins Targeting Mesothelin with CTLA-4 Blockade Synergistically Eradicates Murine Cancer by Promoting Anticancer Immunity.
Yasmin Leshem, James O'Brien, +8 authors, Ira Pastan.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674083    Free PMC article.
Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study.
Yong Qin, Mariana Petaccia de Macedo, +24 authors, Sapna P Patel.
Oncoimmunology, 2017 Jul 07; 6(6). PMID: 28680759    Free PMC article.
Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives.
Clizia Zichi, Marcello Tucci, +5 authors, Massimo Di Maio.
Biomed Res Int, 2017 Jul 07; 2017. PMID: 28680882    Free PMC article.
PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
Tomas Jelinek, Jana Mihalyova, +2 authors, Roman Hajek.
Immunology, 2017 Jul 08; 152(3). PMID: 28685821    Free PMC article.
Presentation, Treatment, and Prognosis of Secondary Melanoma within the Orbit.
Anna M Rose, Sophie Cowen, +2 authors, Geoffrey E Rose.
Front Oncol, 2017 Jul 12; 7. PMID: 28690979    Free PMC article.
Late-Developing Metastatic Malignant Melanoma in the Thoracic Spine Originating from Choroidal Melanoma.
Jun Kyu Hwang, Kyung Hyun Kim, +2 authors, Sung Uk Kuh.
Korean J Spine, 2017 Jul 15; 14(2). PMID: 28704910    Free PMC article.
Rational combinations of immunotherapy for pancreatic ductal adenocarcinoma.
Alex B Blair, Lei Zheng.
Chin Clin Oncol, 2017 Jul 15; 6(3). PMID: 28705008    Free PMC article.
Supportive care for patients undergoing immunotherapy.
Bernardo Leon Rapoport, Ronwyn van Eeden, +4 authors, Devan Moodley.
Support Care Cancer, 2017 Jul 15; 25(10). PMID: 28707167
Immunotherapy for malignant pleural mesothelioma: current status and future directions.
Jordan Dozier, Hua Zheng, Prasad S Adusumilli.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713676    Free PMC article.
The Autophagy Receptor Adaptor p62 is Up-regulated by UVA Radiation in Melanocytes and in Melanoma Cells.
Ashley Sample, Baozhong Zhao, +4 authors, Yu-Ying He.
Photochem Photobiol, 2017 Jul 18; 94(3). PMID: 28715145    Free PMC article.
Acute interstitial nephritis after sequential ipilumumab - nivolumab therapy of metastatic melanoma.
Lea Bottlaender, Anne-Laure Breton, +3 authors, Stephane Dalle.
J Immunother Cancer, 2017 Jul 19; 5(1). PMID: 28716106    Free PMC article.
Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists.
Frédéric Illouz, Claire Briet, +5 authors, Patrice Rodien.
Cancer Med, 2017 Jul 19; 6(8). PMID: 28719055    Free PMC article.
Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
Pedro R Lowenstein, Maria G Castro.
Clin Immunol, 2017 Jul 20; 189. PMID: 28720549    Free PMC article.
Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model.
Jessie R Nedrow, Anders Josefsson, +6 authors, George Sgouros.
EJNMMI Res, 2017 Jul 20; 7(1). PMID: 28721684    Free PMC article.
Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.
Kimberly Loo, Katy K Tsai, +14 authors, Adil I Daud.
JCI Insight, 2017 Jul 21; 2(14). PMID: 28724802    Free PMC article.
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.
Natasha Lakin, Robert Rulach, Stefan Nowicki, Kathreena M Kurian.
Front Oncol, 2017 Jul 22; 7. PMID: 28730140    Free PMC article.
[Malignant melanoma : Current status].
J K Winkler, K Buder-Bakhaya, +2 authors, J C Hassel.
Radiologe, 2017 Jul 22; 57(10). PMID: 28730266
Biologic therapy in esophageal and gastric malignancies: current therapies and future directions.
Pamela Samson, A Craig Lockhart.
J Gastrointest Oncol, 2017 Jul 25; 8(3). PMID: 28736629    Free PMC article.
An elderly man with remote history of metastatic melanoma now with localized pancreas cancer and new liver masses.
Neil Vasan, Maria Ignez Braghiroli, +13 authors, Eileen M O'Reilly.
J Gastrointest Oncol, 2017 Jul 25; 8(3). PMID: 28736647    Free PMC article.
Melanoma subtypes demonstrate distinct PD-L1 expression profiles.
Genevieve J Kaunitz, Tricia R Cottrell, +16 authors, Janis M Taube.
Lab Invest, 2017 Jul 25; 97(9). PMID: 28737763    Free PMC article.
The immune contexture in cancer prognosis and treatment.
Wolf H Fridman, Laurence Zitvogel, Catherine Sautès-Fridman, Guido Kroemer.
Nat Rev Clin Oncol, 2017 Jul 26; 14(12). PMID: 28741618
Highly Cited. Review.
Oesophageal cancer.
Elizabeth C Smyth, Jesper Lagergren, +4 authors, David Cunningham.
Nat Rev Dis Primers, 2017 Jul 28; 3. PMID: 28748917    Free PMC article.
Highly Cited. Review.
Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium.
Brian C Willis, Emily A Sloan, +2 authors, Anne M Mills.
Mod Pathol, 2017 Jul 29; 30(11). PMID: 28752845
Tools to define the melanoma-associated immunopeptidome.
Eva Bräunlein, Angela M Krackhardt.
Immunology, 2017 Jul 30; 152(4). PMID: 28755382    Free PMC article.
Immunotherapy: Who Is Eligible?
Daniel Wang, Jill Gilbert, Young J Kim.
Otolaryngol Clin North Am, 2017 Aug 02; 50(4). PMID: 28755708    Free PMC article.
PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence.
Phu N Tran, Sarmen Sarkissian, Joseph Chao, Samuel J Klempner.
Gastrointest Cancer, 2017 Aug 02; 7. PMID: 28757801    Free PMC article.
New treatment options for metastatic renal cell carcinoma.
Alejo Rodriguez-Vida, Thomas E Hutson, Joaquim Bellmunt, Michiel H Strijbos.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761748    Free PMC article.
Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer.
Tiina Moilanen, Susanna Mustanoja, Peeter Karihtala, Jussi P Koivunen.
ESMO Open, 2017 Aug 02; 2(3). PMID: 28761759    Free PMC article.
Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors.
Kathryn C Arbour, Jarushka Naidoo, +9 authors, Matthew D Hellmann.
PLoS One, 2017 Aug 05; 12(8). PMID: 28771603    Free PMC article.
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy.
Junyu Long, Jianzhen Lin, +7 authors, Haitao Zhao.
J Hematol Oncol, 2017 Aug 05; 10(1). PMID: 28774337    Free PMC article.
Targeting Immune System Alterations in Hodgkin Lymphoma.
Natalie S Grover, Barbara Savoldo.
Curr Hematol Malig Rep, 2017 Aug 07; 12(4). PMID: 28780614    Free PMC article.
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Russell Maxwell, Christopher M Jackson, Michael Lim.
Curr Treat Options Oncol, 2017 Aug 09; 18(8). PMID: 28785997
Hospitalisation costs of metastatic melanoma in France; the MELISSA study (MELanoma In hoSpital coSts Assessment).
Jérôme Fernandes, Bruno Bregman, +4 authors, Anne-Françoise Gaudin.
BMC Health Serv Res, 2017 Aug 10; 17(1). PMID: 28789648    Free PMC article.
Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy.
Rebecca Y Tay, Elizabeth Blackley, +4 authors, Andrew Haydon.
Br J Cancer, 2017 Aug 11; 117(7). PMID: 28797029    Free PMC article.
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
François Bertucci, Anthony Gonçalves.
Curr Oncol Rep, 2017 Aug 12; 19(10). PMID: 28799073
Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
Gaurav Bajaj, Manish Gupta, +2 authors, Amit Roy.
J Clin Pharmacol, 2017 Aug 12; 57(12). PMID: 28800166    Free PMC article.
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin.
Cancer Cell, 2017 Aug 16; 32(2). PMID: 28810147    Free PMC article.
Highly Cited.
Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors.
Sabrina Rossi, Luca Toschi, +3 authors, Egesta Lopci.
Eur J Nucl Med Mol Imaging, 2017 Aug 18; 44(13). PMID: 28815334
Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.
Michael D Jain, John Kuruvilla.
Drugs, 2017 Aug 19; 77(15). PMID: 28819821
Novel Immunotherapies for Multiple Myeloma.
Mattia D'Agostino, Mario Boccadoro, Eric L Smith.
Curr Hematol Malig Rep, 2017 Aug 19; 12(4). PMID: 28819882    Free PMC article.
Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.
William K Decker, Rodrigo F da Silva, +5 authors, Silke Paust.
Front Immunol, 2017 Aug 22; 8. PMID: 28824608    Free PMC article.
Highly Cited. Review.
Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting.
Eva Pike, Vida Hamidi, +2 authors, Marianne Klemp.
BMJ Open, 2017 Aug 23; 7(8). PMID: 28827234    Free PMC article.
Systematic Review.
18F-FDG-PET detects complete response to PD1-therapy in melanoma patients two weeks after therapy start.
Ferdinand Seith, Andrea Forschner, +6 authors, Nina Schwenzer.
Eur J Nucl Med Mol Imaging, 2017 Aug 24; 45(1). PMID: 28831583
Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
Dae-Sun Kim, Himika Dastidar, +14 authors, Douglas J Mahoney.
Nat Commun, 2017 Aug 26; 8(1). PMID: 28839138    Free PMC article.
Immunotherapy in Gynecologic Cancers: Are We There Yet?
Janelle B Pakish, Amir A Jazaeri.
Curr Treat Options Oncol, 2017 Aug 26; 18(10). PMID: 28840453    Free PMC article.
Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Dirk Schadendorf, Jedd D Wolchok, +14 authors, Michael A Postow.
J Clin Oncol, 2017 Aug 26; 35(34). PMID: 28841387    Free PMC article.
Highly Cited.
CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Lena M Kranz, Jan D Beck, +3 authors, Mustafa Diken.
Hum Vaccin Immunother, 2017 Aug 29; 13(10). PMID: 28846471    Free PMC article.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Rachel M Gibbons Johnson, Haidong Dong.
Front Immunol, 2017 Aug 30; 8. PMID: 28848559    Free PMC article.
Synthetic immune niches for cancer immunotherapy.
Jorieke Weiden, Jurjen Tel, Carl G Figdor.
Nat Rev Immunol, 2017 Aug 31; 18(3). PMID: 28853444
Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, +6 authors, Bernard A Fox.
Clin Cancer Res, 2017 Sep 01; 23(20). PMID: 28855348    Free PMC article.
Highly Cited.
Patient and oncologist preferences for attributes of treatments in advanced melanoma: a discrete choice experiment.
Frank Xiaoqing Liu, Edward A Witt, +4 authors, Richard W Joseph.
Patient Prefer Adherence, 2017 Sep 02; 11. PMID: 28860722    Free PMC article.
NRAS-mutant melanoma: current challenges and future prospect.
Eva Muñoz-Couselo, Ester Zamora Adelantado, +2 authors, José Perez-Garcia.
Onco Targets Ther, 2017 Sep 02; 10. PMID: 28860801    Free PMC article.
Tumour radiosensitivity is associated with immune activation in solid tumours.
Tobin Strom, Louis B Harrison, +11 authors, Javier F Torres-Roca.
Eur J Cancer, 2017 Sep 02; 84. PMID: 28863385    Free PMC article.
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies.
Lillian L Siu, S Percy Ivy, +3 authors, Gary L Rosner.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864723    Free PMC article.
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Valsamo Anagnostou, Mark Yarchoan, +6 authors, Patrick M Forde.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864724    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Christina S Baik, Eric H Rubin, +5 authors, Laura Q M Chow.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864727    Free PMC article.
Immune checkpoint inhibitors in cancer therapy.
Eika S Webb, Peng Liu, +3 authors, Yao-He Wang.
J Biomed Res, 2017 Sep 04; 32(5). PMID: 28866656    Free PMC article.
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation.
Eddie Gibson, Ian Koblbauer, +8 authors, Michael Lees.
Pharmacoeconomics, 2017 Sep 04; 35(12). PMID: 28866758    Free PMC article.
Precision Medicine and PET/Computed Tomography in Melanoma.
Esther Mena, Yasemin Sanli, Charles Marcus, Rathan M Subramaniam.
PET Clin, 2017 Sep 05; 12(4). PMID: 28867115    Free PMC article.
Systemic BRAF/MEK Inhibitors as a Potential Treatment Option in Metastatic Conjunctival Melanoma.
Joel M Mor, Ludwig M Heindl.
Ocul Oncol Pathol, 2017 Sep 05; 3(2). PMID: 28868285    Free PMC article.
[Immunotherapy as modern tumor treatment].
C Grüllich.
Radiologe, 2017 Sep 06; 57(10). PMID: 28871357
PD1 signal transduction pathways in T cells.
Hugo Arasanz, Maria Gato-Cañas, +4 authors, David Escors.
Oncotarget, 2017 Sep 09; 8(31). PMID: 28881701    Free PMC article.
Highly Cited. Review.
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis.
Adam K Karlsson, Sohag N Saleh.
Clin Cosmet Investig Dermatol, 2017 Sep 09; 10. PMID: 28883738    Free PMC article.
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, +30 authors, James Larkin.
N Engl J Med, 2017 Sep 12; 377(14). PMID: 28889792    Free PMC article.
Highly Cited.
The changing landscape of dermatology practice: melanoma and pump-probe laser microscopy.
Charles J Puza, Warren S Warren, Paul J Mosca.
Lasers Med Sci, 2017 Sep 12; 32(8). PMID: 28890988
Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events.
Marianne Davies, Emily A Duffield.
Immunotargets Ther, 2017 Sep 13; 6. PMID: 28894725    Free PMC article.
Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.
Ying Zhang, Raj Kurupati, +17 authors, Hildegund C J Ertl.
Cancer Cell, 2017 Sep 13; 32(3). PMID: 28898698    Free PMC article.
Highly Cited.
PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.
Benjamin A Kansy, Fernando Concha-Benavente, +13 authors, Robert L Ferris.
Cancer Res, 2017 Sep 15; 77(22). PMID: 28904066    Free PMC article.
Highly Cited.
Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Thomas B Huffaker, Soh-Hyun Lee, +11 authors, Ryan M O'Connell.
J Biol Chem, 2017 Sep 16; 292(45). PMID: 28912267    Free PMC article.
Emerging biomarkers for cancer immunotherapy in melanoma.
Margaret L Axelrod, Douglas B Johnson, Justin M Balko.
Semin Cancer Biol, 2017 Sep 18; 52(Pt 2). PMID: 28917578    Free PMC article.
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Julia Dai, Viswanath R Belum, +2 authors, Mario E Lacouture.
J Am Acad Dermatol, 2017 Sep 19; 77(5). PMID: 28918974    Free PMC article.
Systematic Review.
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Sulsal Haque, Mahender Yellu, Jaskirat Randhawa, Nooshin Hashemi-Sadraei.
Drug Des Devel Ther, 2017 Sep 19; 11. PMID: 28919706    Free PMC article.
Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.
Nicolas Jacquelot, Jonathan M Pitt, +5 authors, Laurence Zitvogel.
Oncoimmunology, 2017 Sep 19; 6(8). PMID: 28919986    Free PMC article.
High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute.
Diwakar Davar, Fei Ding, +4 authors, Hussein A Tawbi.
J Immunother Cancer, 2017 Sep 20; 5(1). PMID: 28923120    Free PMC article.
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab.
Petros Fessas, Hassal Lee, Shinji Ikemizu, Tobias Janowitz.
Semin Oncol, 2017 Sep 20; 44(2). PMID: 28923212    Free PMC article.
Targets for immunotherapy of liver cancer.
Tim F Greten, Bruno Sangro.
J Hepatol, 2017 Sep 20;. PMID: 28923358    Free PMC article.
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients.
Arthur E Frankel, Laura A Coughlin, +4 authors, Andrew Y Koh.
Neoplasia, 2017 Sep 20; 19(10). PMID: 28923537    Free PMC article.
Highly Cited.
Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma.
Xiaowen Wu, Junya Yan, +11 authors, Jun Guo.
Oncol Lett, 2017 Sep 21; 14(3). PMID: 28927118    Free PMC article.
Predictors of responses to immune checkpoint blockade in advanced melanoma.
N Jacquelot, M P Roberti, +47 authors, L Zitvogel.
Nat Commun, 2017 Sep 21; 8(1). PMID: 28928380    Free PMC article.
Highly Cited.
A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition.
Chang Gong, Oleg Milberg, +4 authors, Aleksander S Popel.
J R Soc Interface, 2017 Sep 22; 14(134). PMID: 28931635    Free PMC article.
Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade.
David M Miller, Beverly E Faulkner-Jones, James R Stone, Reed E Drews.
JAAD Case Rep, 2017 Sep 22; 3(5). PMID: 28932782    Free PMC article.
PD-L1 is an activation-independent marker of brown adipocytes.
Jessica R Ingram, Michael Dougan, +12 authors, Hidde L Ploegh.
Nat Commun, 2017 Sep 25; 8(1). PMID: 28935898    Free PMC article.
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.
Sasagu Kurozumi, Takaaki Fujii, +4 authors, Hiroyuki Kuwano.
Med Mol Morphol, 2017 Sep 25; 50(4). PMID: 28936553
Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.
Xiaohui Wang, Zhengqiang Bao, +7 authors, Songmin Ying.
Oncotarget, 2017 Sep 25; 8(35). PMID: 28938692    Free PMC article.
Systemic Chemotherapy for Advanced Hepatocellular Carcinoma: Past, Present, and Future.
Masafumi Ikeda, Shuichi Mitsunaga, +5 authors, Takuji Okusaka.
Diseases, 2015 Dec 01; 3(4). PMID: 28943630    Free PMC article.
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.
Donastas Sakellariou-Thompson, Marie-Andrée Forget, +20 authors, Chantale Bernatchez.
Clin Cancer Res, 2017 Sep 28; 23(23). PMID: 28947567    Free PMC article.
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
P B Chapman, C Robert, +15 authors, G A McArthur.
Ann Oncol, 2017 Sep 30; 28(10). PMID: 28961848    Free PMC article.
Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma.
Sugabramya Kuru, Nazia Khan, Hamid Shaaban.
Int J Crit Illn Inj Sci, 2017 Oct 04; 7(3). PMID: 28971033    Free PMC article.
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Romualdo Barroso-Sousa, William T Barry, +4 authors, Sara M Tolaney.
JAMA Oncol, 2017 Oct 04; 4(2). PMID: 28973656    Free PMC article.
Highly Cited. Systematic Review.
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
Mengnan He, Yan Chai, +6 authors, George F Gao.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978021    Free PMC article.
Unusual case of immune-related colitis.
Meltiady Issa, Ioannis Milioglou.
BMJ Case Rep, 2017 Oct 06; 2017. PMID: 28978598    Free PMC article.
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Jason Chesney, Igor Puzanov, +15 authors, Howard L Kaufman.
J Clin Oncol, 2017 Oct 06; 36(17). PMID: 28981385    Free PMC article.
Highly Cited.
Immune checkpoint blockade in infectious diseases.
Michelle N Wykes, Sharon R Lewin.
Nat Rev Immunol, 2017 Oct 11; 18(2). PMID: 28990586    Free PMC article.
Highly Cited. Review.
Genetic Characterization of Brain Metastases in the Era of Targeted Therapy.
Catherine H Han, Priscilla K Brastianos.
Front Oncol, 2017 Oct 11; 7. PMID: 28993799    Free PMC article.
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Nusrat Jahan, Hammad Talat, William T Curry.
Neuro Oncol, 2017 Oct 11; 20(1). PMID: 29016879    Free PMC article.
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Jin Wang, Tongxin Xie, +5 authors, Carlos Caulin.
Cancer Prev Res (Phila), 2017 Oct 12; 10(12). PMID: 29018057    Free PMC article.
Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016.
Paolo A Ascierto, Bruno Daniele, +5 authors, Sandro Pignata.
J Transl Med, 2017 Oct 13; 15(1). PMID: 29020960    Free PMC article.
Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis.
Peng-Fei Cui, Jun-Xun Ma, +3 authors, Yi Hu.
Ther Clin Risk Manag, 2017 Oct 14; 13. PMID: 29026313    Free PMC article.
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Raghad M Abdul-Karim, C Lance Cowey.
Cancer Manag Res, 2017 Oct 14; 9. PMID: 29026335    Free PMC article.
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
Jeffrey E Gershenwald, Richard A Scolyer, +13 authors, for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform.
CA Cancer J Clin, 2017 Oct 14; 67(6). PMID: 29028110    Free PMC article.
Highly Cited.
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.
Tara C Gangadhar, Wen-Jen Hwu, +14 authors, April K S Salama.
J Immunother, 2017 Oct 14; 40(9). PMID: 29028788    Free PMC article.
CD4 and CD8 T lymphocyte interplay in controlling tumor growth.
Dmitrij Ostroumov, Nora Fekete-Drimusz, +2 authors, Norman Woller.
Cell Mol Life Sci, 2017 Oct 17; 75(4). PMID: 29032503    Free PMC article.
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.
Isobel S Okoye, Michael Houghton, +2 authors, Shokrollah Elahi.
Front Immunol, 2017 Oct 17; 8. PMID: 29033936    Free PMC article.
Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.
Charissa A C Jessurun, Julien A M Vos, Jacqueline Limpens, Rosalie M Luiten.
Front Oncol, 2017 Oct 17; 7. PMID: 29034210    Free PMC article.
Immune engineering: from systems immunology to engineering immunity.
Ning Jiang.
Curr Opin Biomed Eng, 2017 Oct 19; 1. PMID: 29038795    Free PMC article.
Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.
Margaret K Callahan, Harriet Kluger, +9 authors, Mario Sznol.
J Clin Oncol, 2017 Oct 19; 36(4). PMID: 29040030    Free PMC article.
Highly Cited.
NCCTG N0879 (Alliance): A randomized phase 2 cooperative group trial of carboplatin, paclitaxel, and bevacizumab ± everolimus for metastatic melanoma.
Robert R McWilliams, Jacob B Allred, +10 authors, Svetomir N Markovic.
Cancer, 2017 Oct 19; 124(3). PMID: 29044496    Free PMC article.
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma.
M H Pollack, A Betof, +9 authors, A N Shoushtari.
Ann Oncol, 2017 Oct 19; 29(1). PMID: 29045547    Free PMC article.
Highly Cited.
Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma.
Taku Fujimura, Takanori Hidaka, +10 authors, Setsuya Aiba.
Oncotarget, 2017 Oct 21; 8(41). PMID: 29050354    Free PMC article.
A case of autosplenectomy associated with T-cell checkpoint inhibitor treatment.
Rachel Delahunty, Margaret Lee, Mineesh Datta, Phillip Parente.
BMJ Case Rep, 2017 Oct 22; 2017. PMID: 29054936    Free PMC article.
Emerging and investigational therapies for neuroblastoma.
Mark A Applebaum, Ami V Desai, Julia L Glade Bender, Susan L Cohn.
Expert Opin Orphan Drugs, 2017 Oct 25; 5(4). PMID: 29062613    Free PMC article.
Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma.
Valentina Rigo, Laura Emionite, +6 authors, Michela Croce.
Sci Rep, 2017 Oct 27; 7(1). PMID: 29070883    Free PMC article.
An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.
Felicity C Stark, Risini D Weeratna, +4 authors, Lakshmi Krishnan.
Vaccines (Basel), 2017 Oct 27; 5(4). PMID: 29072624    Free PMC article.
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy.
Hyunju Lee, F Stephen Hodi, +13 authors, Le Min.
Cancer Immunol Res, 2017 Oct 29; 5(12). PMID: 29079654    Free PMC article.
Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury.
Gary Joseph Doherty, Adam M Duckworth, +5 authors, Pippa G Corrie.
ESMO Open, 2017 Oct 31; 2(4). PMID: 29081991    Free PMC article.
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.
Hilary R Keller, Xin Zhang, +2 authors, James W Wells.
Oncotarget, 2017 Nov 02; 8(43). PMID: 29088901    Free PMC article.
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis.
Peng-Fei Wang, Yang Chen, +5 authors, Chang-Xiang Yan.
Front Pharmacol, 2017 Nov 03; 8. PMID: 29093678    Free PMC article.
Highly Cited.
Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
Brendan L Horton, Jason B Williams, +2 authors, Thomas F Gajewski.
Cancer Immunol Res, 2017 Nov 04; 6(1). PMID: 29097422    Free PMC article.
Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial.
Selma Ugurel, Carmen Loquai, +18 authors, Jürgen C Becker.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100289    Free PMC article.
BRAF inhibitors: resistance and the promise of combination treatments for melanoma.
Merope Griffin, Daniele Scotto, +13 authors, Sophia N Karagiannis.
Oncotarget, 2017 Nov 05; 8(44). PMID: 29100459    Free PMC article.
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives.
Lidia M Yshii, Reinhard Hohlfeld, Roland S Liblau.
Nat Rev Neurol, 2017 Nov 07; 13(12). PMID: 29104289
Cardiotoxicity of immune checkpoint inhibitors.
Gilda Varricchi, Maria Rosaria Galdiero, +5 authors, Carlo Gabriele Tocchetti.
ESMO Open, 2017 Nov 07; 2(4). PMID: 29104763    Free PMC article.
Highly Cited. Review.
Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143.
Antonio Omuro, Gordana Vlahovic, +13 authors, John H Sampson.
Neuro Oncol, 2017 Nov 07; 20(5). PMID: 29106665    Free PMC article.
Highly Cited.
Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release.
María B Pampena, María M Barrio, +4 authors, Estrella Mariel Levy.
Front Immunol, 2017 Nov 08; 8. PMID: 29109725    Free PMC article.
The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts.
Xiaolei Shi, Alpaslan Tasdogan, +3 authors, Ralph J DeBerardinis.
Sci Adv, 2017 Nov 08; 3(11). PMID: 29109980    Free PMC article.
miRNAs, Melanoma and Microenvironment: An Intricate Network.
Gabriele Romano, Lawrence N Kwong.
Int J Mol Sci, 2017 Nov 08; 18(11). PMID: 29112174    Free PMC article.
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
R J Lee, G Gremel, +8 authors, R Marais.
Ann Oncol, 2017 Nov 08; 29(2). PMID: 29112704    Free PMC article.
Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management.
Stefania Stucci, Raffaele Palmirotta, +6 authors, Franco Silvestris.
Oncol Lett, 2017 Nov 09; 14(5). PMID: 29113194    Free PMC article.
SEOM clinical guideline for the management of malignant melanoma (2017).
A Berrocal, A Arance, +7 authors, S M Algarra.
Clin Transl Oncol, 2017 Nov 09; 20(1). PMID: 29116432    Free PMC article.
Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion.
Lee A Albacker, Jeremy Wu, +5 authors, Juliann Chmielecki.
PLoS One, 2017 Nov 10; 12(11). PMID: 29121062    Free PMC article.
Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis.
Daniel Y Wang, Fei Ye, Shilin Zhao, Douglas B Johnson.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123955    Free PMC article.
Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade.
Haoran Zha, Xiao Han, +5 authors, Bo Zhu.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123963    Free PMC article.
Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis.
Xin Li, Junpeng Wang, +6 authors, Liying Wang.
Oncotarget, 2017 Nov 16; 8(48). PMID: 29137370    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines.
Bradley Garman, Ioannis N Anastopoulos, +31 authors, Katherine L Nathanson.
Cell Rep, 2017 Nov 16; 21(7). PMID: 29141224    Free PMC article.
Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.
Gabriele Gamerith, Arno Amann, +7 authors, Heinz Zwierzina.
Oncol Lett, 2017 Nov 17; 14(5). PMID: 29142605    Free PMC article.
Role of Adjuvant Treatment in Sinonasal Mucosal Melanoma.
Moran Amit, Samantha Tam, +5 authors, Ehab Y Hanna.
J Neurol Surg B Skull Base, 2017 Nov 17; 78(6). PMID: 29142805    Free PMC article.
Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016.
Paolo A Ascierto, Sanjiv S Agarwala, +20 authors, Magdalena Thurin.
J Transl Med, 2017 Nov 18; 15(1). PMID: 29145885    Free PMC article.
Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
Mark Owyong, Niloufar Hosseini-Nassab, +4 authors, Bryan Ronain Smith.
Drug Resist Updat, 2017 Nov 18; 33-35. PMID: 29145972    Free PMC article.
Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Dhanusha Sabanathan, John J Park, +3 authors, Howard Gurney.
Oncologist, 2017 Nov 18; 22(12). PMID: 29146617    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
Evolving Paradigms in Melanoma Therapy.
Anthony J Olszanski, Brianna W Hoffner.
J Adv Pract Oncol, 2016 Apr 01; 7(3). PMID: 29152391    Free PMC article.
Melanoma: Genetic Abnormalities, Tumor Progression, Clonal Evolution and Tumor Initiating Cells.
Ugo Testa, Germana Castelli, Elvira Pelosi.
Med Sci (Basel), 2017 Nov 22; 5(4). PMID: 29156643    Free PMC article.
Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer.
Zachary J Brown, Bernd Heinrich, +2 authors, Tim F Greten.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157287    Free PMC article.
Biomarkers for immunotherapy in bladder cancer: a moving target.
David H Aggen, Charles G Drake.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157296    Free PMC article.
Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?
Gustavo Dos Santos Fernandes, Daniel da Motta Girardi, +2 authors, Renata de Almeida Coudry.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157298    Free PMC article.
Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma.
Rahima Jamal, Réjean Lapointe, +13 authors, Wilson H Miller.
J Immunother Cancer, 2017 Nov 22; 5(1). PMID: 29157311    Free PMC article.
Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity.
Nan Guo Ring, Dietmar Herndler-Brandstetter, +11 authors, Irving L Weissman.
Proc Natl Acad Sci U S A, 2017 Nov 22; 114(49). PMID: 29158380    Free PMC article.
Highly Cited.
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience.
Takeo Fujii, Rivka R Colen, +19 authors, Aung Naing.
Invest New Drugs, 2017 Nov 22; 36(4). PMID: 29159766    Free PMC article.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
I Puzanov, A Diab, +19 authors, Society for Immunotherapy of Cancer Toxicity Management Working Group.
J Immunother Cancer, 2017 Nov 23; 5(1). PMID: 29162153    Free PMC article.
Highly Cited.
Targeting immune checkpoints in breast cancer: an update of early results.
Cinzia Solinas, Andrea Gombos, +3 authors, Laurence Buisseret.
ESMO Open, 2017 Nov 28; 2(5). PMID: 29177095    Free PMC article.
Can checkpoint inhibitor therapy improve response to chemotherapy?
Michael Constantin Kirchberger, Bastian Schilling, +3 authors, Lucie Heinzerling.
J Cancer Res Clin Oncol, 2017 Nov 28; 144(1). PMID: 29177557
Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.
Wojciech K Panek, J Robert Kane, +4 authors, Maciej S Lesniak.
Oncotarget, 2017 Nov 29; 8(51). PMID: 29179527    Free PMC article.
Combined inhibition of MEK and nuclear ERK translocation has synergistic antitumor activity in melanoma cells.
Rand Arafeh, Karen Flores, +5 authors, Yardena Samuels.
Sci Rep, 2017 Nov 29; 7(1). PMID: 29180761    Free PMC article.
CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells.
Meagan R Rollins, Rachel M Gibbons Johnson.
J Immunol Res, 2017 Nov 29; 2017. PMID: 29181416    Free PMC article.
Melanoma in 2017: Moving treatments earlier to move further forwards.
Michael A Davies, Keith T Flaherty.
Nat Rev Clin Oncol, 2017 Nov 29; 15(2). PMID: 29182162    Free PMC article.
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.
Nina Frey, Sascha Venturelli, Lars Zender, Michael Bitzer.
Nat Rev Gastroenterol Hepatol, 2017 Dec 01; 15(2). PMID: 29184185
Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.
Christina H Son, Gini F Fleming, John W Moroney.
Cancer Manag Res, 2017 Dec 01; 9. PMID: 29184441    Free PMC article.
Development of a Diagnostic Programmed Cell Death 1-Ligand 1 Immunohistochemistry Assay for Nivolumab Therapy in Melanoma.
Therese Phillips, Molly M Millett, +14 authors, Henrik Winther.
Appl Immunohistochem Mol Morphol, 2017 Dec 01; 26(1). PMID: 29189265    Free PMC article.
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.
Paul J Carter, Greg A Lazar.
Nat Rev Drug Discov, 2017 Dec 02; 17(3). PMID: 29192287
Highly Cited. Review.
Implications of the tumor immune microenvironment for staging and therapeutics.
Janis M Taube, Jérôme Galon, +8 authors, Ashley Cimino-Mathews.
Mod Pathol, 2017 Dec 02; 31(2). PMID: 29192647    Free PMC article.
Highly Cited. Review.
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
Silvana Morello, Mariaelena Capone, +6 authors, Paolo Antonio Ascierto.
J Transl Med, 2017 Dec 06; 15(1). PMID: 29202855    Free PMC article.
Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.
Franz Villarroel-Espindola, Xiaoqing Yu, +9 authors, Kurt A Schalper.
Clin Cancer Res, 2017 Dec 06; 24(7). PMID: 29203588    Free PMC article.
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
Arlene Siefker-Radtke, Brendan Curti.
Nat Rev Urol, 2017 Dec 06; 15(2). PMID: 29205200
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Anna C Filley, Mario Henriquez, Mahua Dey.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207684    Free PMC article.
Highly Cited. Review.
Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Robert J Torphy, Richard D Schulick, Yuwen Zhu.
Int J Mol Sci, 2017 Dec 07; 18(12). PMID: 29211042    Free PMC article.
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence.
Katherine R Singleton, Lorin Crawford, +19 authors, Kris C Wood.
Cell Rep, 2017 Dec 07; 21(10). PMID: 29212027    Free PMC article.
Systemic Treatment of Metastatic Conjunctival Melanoma.
Simão Pinto Torres, Teresa André, +2 authors, Maria José Passos.
Case Rep Oncol Med, 2017 Dec 08; 2017. PMID: 29214089    Free PMC article.
Aberrant SIRT6 expression contributes to melanoma growth: Role of the autophagy paradox and IGF-AKT signaling.
Liwen Wang, Weinan Guo, +11 authors, Chunying Li.
Autophagy, 2017 Dec 08; 14(3). PMID: 29215322    Free PMC article.
Ablation of Transcription Factor IRF4 Promotes Transplant Acceptance by Driving Allogenic CD4+ T Cell Dysfunction.
Jie Wu, Hedong Zhang, +9 authors, Wenhao Chen.
Immunity, 2017 Dec 10; 47(6). PMID: 29221730    Free PMC article.
Towards personalized, tumour-specific, therapeutic vaccines for cancer.
Zhuting Hu, Patrick A Ott, Catherine J Wu.
Nat Rev Immunol, 2017 Dec 12; 18(3). PMID: 29226910    Free PMC article.
Highly Cited. Review.
Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome.
Andres Chang, Danielle Schlafer, Christopher R Flowers, Pamela B Allen.
Expert Opin Investig Drugs, 2017 Dec 13; 27(1). PMID: 29228840    Free PMC article.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
Mark Lawler, Deborah Alsina, +19 authors, Bowel Cancer UK Critical Research Gaps in Colorectal Cancer Initiative.
Gut, 2017 Dec 14; 67(1). PMID: 29233930    Free PMC article.
Thyroid dysfunctions secondary to cancer immunotherapy.
P Chalan, G Di Dalmazi, +3 authors, P Caturegli.
J Endocrinol Invest, 2017 Dec 15; 41(6). PMID: 29238906    Free PMC article.
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.
Ashley V Kroll, Ronnie H Fang, +8 authors, Liangfang Zhang.
Adv Mater, 2017 Dec 15; 29(47). PMID: 29239517    Free PMC article.
Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Young Kwang Chae, Michael S Oh, Francis J Giles.
Oncologist, 2017 Dec 16; 23(4). PMID: 29242279    Free PMC article.
Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.
Adam C Palmer, Peter K Sorger.
Cell, 2017 Dec 16; 171(7). PMID: 29245013    Free PMC article.
Highly Cited.
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Andrea Botticelli, Concetta Elisa Onesti, +15 authors, Paolo Marchetti.
Oncotarget, 2017 Dec 17; 8(59). PMID: 29245905    Free PMC article.
Hypokalemic Paralysis Secondary to Immune Checkpoint Inhibitor Therapy.
Pragathi Balakrishna, Augusto Villegas.
Case Rep Oncol Med, 2017 Dec 19; 2017. PMID: 29250451    Free PMC article.
The Most Recent Oncologic Emergency: What Emergency Physicians Need to Know About the Potential Complications of Immune Checkpoint Inhibitors.
Duncan Simmons, Eddy Lang.
Cureus, 2017 Dec 19; 9(10). PMID: 29250474    Free PMC article.
PD-L1 Promotes Self-Renewal and Tumorigenicity of Malignant Melanoma Initiating Cells.
Fang Zheng, Jianzhong Dang, +3 authors, Fanjun Cheng.
Biomed Res Int, 2017 Dec 19; 2017. PMID: 29250533    Free PMC article.
Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices.
C Lance Cowey, Frank Xiaoqing Liu, +4 authors, Scot W Ebbinghaus.
J Immunother, 2017 Dec 19; 41(2). PMID: 29252916    Free PMC article.
Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma.
Yutaka Takahashi, Tomohiro Yasui, +7 authors, Kazuhiko Ogawa.
PLoS One, 2017 Dec 19; 12(12). PMID: 29253865    Free PMC article.
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry.
Brendan Curti, Gregory A Daniels, +10 authors, Janice P Dutcher.
J Immunother Cancer, 2017 Dec 20; 5(1). PMID: 29254506    Free PMC article.
Bifidobacterium can mitigate intestinal immunopathology in the context of CTLA-4 blockade.
Feng Wang, Qian Yin, Liang Chen, Mark M Davis.
Proc Natl Acad Sci U S A, 2017 Dec 20; 115(1). PMID: 29255057    Free PMC article.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
The current status of immunobased therapies for metastatic renal-cell carcinoma.
Niranjan J Sathianathen, Suprita Krishna, +4 authors, Thomas S Griffith.
Immunotargets Ther, 2017 Dec 20; 6. PMID: 29255699    Free PMC article.
A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Rachel E Sanborn, Helen J Ross, +12 authors, Bernard A Fox.
J Immunother Cancer, 2017 Dec 21; 5(1). PMID: 29258618    Free PMC article.
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.
Claire Lhuillier, Claire Vanpouille-Box, +2 authors, Sandra Demaria.
Semin Cancer Biol, 2017 Dec 21; 52(Pt 2). PMID: 29258856    Free PMC article.
Solanum incanum extract (SR-T100) induces melanoma cell apoptosis and inhibits established lung metastasis.
Sebastian Yu, Hamm-Ming Sheu, Chih-Hung Lee.
Oncotarget, 2017 Dec 22; 8(61). PMID: 29262580    Free PMC article.
A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.
Hongwei Tian, Gang Shi, +12 authors, Hongxin Deng.
Signal Transduct Target Ther, 2017 Dec 22; 1. PMID: 29263903    Free PMC article.
Readministration of Nivolumab after Persistent Immune-related Colitis in a Patient with Recurrent Melanoma.
Yosuke Fujii, Yoshitaka Nishikawa, +4 authors, Manabu Muto.
Intern Med, 2017 Dec 23; 57(8). PMID: 29269640    Free PMC article.
TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma.
Florie Bertrand, Anne Montfort, +9 authors, Bruno Ségui.
Nat Commun, 2017 Dec 24; 8(1). PMID: 29273790    Free PMC article.
Highly Cited.
Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.
Hassan Sadozai, Thomas Gruber, Robert Emil Hunger, Mirjam Schenk.
Front Immunol, 2017 Dec 26; 8. PMID: 29276510    Free PMC article.
The biology and therapeutic management of melanoma brain metastases.
Daniel Abate-Daga, Maria C Ramello, +2 authors, Keiran S M Smalley.
Biochem Pharmacol, 2017 Dec 27; 153. PMID: 29278675    Free PMC article.
How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know.
Marianne Davies.
J Adv Pract Oncol, 2016 Jul 01; 7(5). PMID: 29282426    Free PMC article.
Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Ioannis Karydis, Alexandra Gangi, +11 authors, Christian Ottensmeier.
J Surg Oncol, 2017 Dec 29; 117(6). PMID: 29284076    Free PMC article.
Generating the Abscopal Effect by Combining Proapoptotic Peptides With IL-12-Based Immunotherapy.
Filipe Martins, Grégoire Stalder, Michel Obeid.
Neoplasia, 2017 Dec 30; 20(2). PMID: 29287248    Free PMC article.
Immune Checkpoint Inhibitors in Melanoma and HIV Infection.
Antonio Marra, Giosuè Scognamiglio, +6 authors, Francesco Sabbatino.
Open AIDS J, 2018 Jan 02; 11. PMID: 29290886    Free PMC article.
Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity.
Yuan Zhang, Na Li, Heikyung Suh, Darrell J Irvine.
Nat Commun, 2018 Jan 04; 9(1). PMID: 29295974    Free PMC article.
Highly Cited.
PD-L1 inhibitors in the pipeline: Promise and progress.
Vito Vanella, Lucia Festino, +3 authors, Paolo A Ascierto.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296516    Free PMC article.
Diffuse granulomatous panniculitis associated with anti PD-1 antibody therapy.
Baijia Jiang, Maria M Patino, +4 authors, Kevin B Kim.
JAAD Case Rep, 2018 Jan 04; 4(1). PMID: 29296642    Free PMC article.
High-grade neutropenia in a patient successfully treated with nivolumab for refractory primary mediastinal B-cell lymphoma.
Zachary Wright, Alexander Brown.
Blood Adv, 2018 Jan 04; 1(17). PMID: 29296772    Free PMC article.
Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma.
Reid W Merryman, Philippe Armand, Kyle T Wright, Scott J Rodig.
Blood Adv, 2018 Jan 04; 1(26). PMID: 29296917    Free PMC article.
Highly Cited. Review.
Modulating Tumor Immunology by Inhibiting Indoleamine 2,3-Dioxygenase (IDO): Recent Developments and First Clinical Experiences.
Diwakar Davar, Nathan Bahary.
Target Oncol, 2018 Jan 06; 13(2). PMID: 29302770
The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors.
Heinz Läubli, Viktor H Koelzer, +6 authors, Alfred Zippelius.
Oncoimmunology, 2018 Jan 09; 7(2). PMID: 29308309    Free PMC article.
Early B cell changes predict autoimmunity following combination immune checkpoint blockade.
Rituparna Das, Noffar Bar, +10 authors, Kavita M Dhodapkar.
J Clin Invest, 2018 Jan 09; 128(2). PMID: 29309048    Free PMC article.
Highly Cited.
B cells as biomarkers: predicting immune checkpoint therapy adverse events.
Shannon M Liudahl, Lisa M Coussens.
J Clin Invest, 2018 Jan 09; 128(2). PMID: 29309049    Free PMC article.
The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Suzanne A B M Aarts, Tom T P Seijkens, +3 authors, Esther Lutgens.
Front Immunol, 2018 Jan 10; 8. PMID: 29312317    Free PMC article.
Neoantigen Targeting-Dawn of a New Era in Cancer Immunotherapy?
Thomas C Wirth, Florian Kühnel.
Front Immunol, 2018 Jan 10; 8. PMID: 29312332    Free PMC article.
Highly Cited. Review.
A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis.
Katsuya Sakai, Hitoshi Mochizuki, +3 authors, Masamitsu Nakazato.
Case Rep Med, 2018 Jan 10; 2017. PMID: 29312452    Free PMC article.
Impact of oncogenic pathways on evasion of antitumour immune responses.
Stefani Spranger, Thomas F Gajewski.
Nat Rev Cancer, 2018 Jan 13; 18(3). PMID: 29326431    Free PMC article.
Highly Cited. Review.
A novel biologic platform elicits profound T cell costimulatory activity and antitumor immunity in mice.
Joseph M Ryan, Payal Mittal, +4 authors, Anthony T Vella.
Cancer Immunol Immunother, 2018 Jan 13; 67(4). PMID: 29327109    Free PMC article.
The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
Rosa Nguyen, Jim Houston, +2 authors, Michael A Dyer.
Cancer Immunol Immunother, 2018 Jan 13; 67(4). PMID: 29327110    Free PMC article.
A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma.
Lukas Krähenbühl, Simone M Goldinger, +7 authors, Phil F Cheng.
Neoplasia, 2018 Jan 15; 20(2). PMID: 29331888    Free PMC article.
Neurologic complications of immune checkpoint inhibitors.
Avi Fellner, Chen Makranz, +11 authors, Shlomit Yust-Katz.
J Neurooncol, 2018 Jan 15; 137(3). PMID: 29332184
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports.
Stefan Schliep, Abbas Agaimy, +3 authors, Lucie Heinzerling.
J Immunother Cancer, 2018 Jan 16; 6(1). PMID: 29332608    Free PMC article.
Why do women with melanoma do better than men?
Keiran Sm Smalley.
Elife, 2018 Jan 18; 7. PMID: 29336304    Free PMC article.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Heng Lin, Shuang Wei, +16 authors, Weiping Zou.
J Clin Invest, 2018 Jan 18; 128(2). PMID: 29337305    Free PMC article.
Highly Cited.
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.
Gwendolyn J McGinnis, Jacob Raber.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338610    Free PMC article.
TUSC2 Immunogene Therapy Synergizes with Anti-PD-1 through Enhanced Proliferation and Infiltration of Natural Killer Cells in Syngeneic Kras-Mutant Mouse Lung Cancer Models.
Ismail M Meraz, Mourad Majidi, +8 authors, Jack A Roth.
Cancer Immunol Res, 2018 Jan 18; 6(2). PMID: 29339375    Free PMC article.
Urgent Need to Define Pretreatment Predictors of Immune Check Point Inhibitors Related Endocrinopathies: A Case Report and Review of Literature.
Vishal Sehgal, Richard Childress.
J Transl Int Med, 2018 Jan 18; 5(4). PMID: 29340281    Free PMC article.
Unleashing the tiger - iatrogenic autoimmunity from cancer immunotherapy drugs.
Queenie Luu, Gabor Major.
JRSM Open, 2018 Jan 19; 9(1). PMID: 29344404    Free PMC article.
Checkpoint Inhibitors, Palliative Care, or Hospice.
Mellar P Davis, Rajiv Panikkar.
Curr Oncol Rep, 2018 Jan 20; 20(1). PMID: 29349518
Hypermutated Tumors and Immune Checkpoint Inhibition.
Kristen K Ciombor, Richard M Goldberg.
Drugs, 2018 Jan 20; 78(2). PMID: 29350327
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
Jun Gong, Alexander Chehrazi-Raffle, Srikanth Reddi, Ravi Salgia.
J Immunother Cancer, 2018 Jan 24; 6(1). PMID: 29357948    Free PMC article.
Highly Cited. Review.
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy.
Wen Cheng, Dian Fu, Feng Xu, Zhengyu Zhang.
Oncogenesis, 2018 Jan 24; 7(1). PMID: 29358573    Free PMC article.
Clinical Development of PD-1 in Advanced Melanoma.
Rodrigo Ramella Munhoz, Michael Andrew Postow.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360722    Free PMC article.
Toxicities Associated With PD-1/PD-L1 Blockade.
Daniel Y Wang, Douglas B Johnson, Elizabeth J Davis.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360726    Free PMC article.
Mechanisms of Resistance to PD-1 and PD-L1 Blockade.
Theodore S Nowicki, Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360728    Free PMC article.
Highly Cited. Review.
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Dok Hyun Yoon, Mark J Osborn, Jakub Tolar, Chong Jai Kim.
Int J Mol Sci, 2018 Jan 25; 19(2). PMID: 29364163    Free PMC article.
Highly Cited. Review.
Cancer immunology and melanoma immunotherapy.
Rudinei Diogo Marques Linck, Rômulo Leopoldo de Paula Costa, Bernardo Garicochea.
An Bras Dermatol, 2018 Jan 25; 92(6). PMID: 29364441    Free PMC article.
Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors.
Shifaa M Abdin, Dana M Zaher, El-Shaimaa A Arafa, Hany A Omar.
Cancers (Basel), 2018 Jan 26; 10(2). PMID: 29370105    Free PMC article.
Cell death-based treatments of melanoma:conventional treatments and new therapeutic strategies.
Gianfranco Mattia, Rossella Puglisi, +3 authors, Paola Matarrese.
Cell Death Dis, 2018 Jan 27; 9(2). PMID: 29371600    Free PMC article.
Highly Cited. Review.
HDAC inhibition potentiates immunotherapy in triple negative breast cancer.
Manuela Terranova-Barberio, Scott Thomas, +6 authors, Pamela N Munster.
Oncotarget, 2018 Jan 27; 8(69). PMID: 29371976    Free PMC article.
Highly Cited.
Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.
Adam Diehl, Mark Yarchoan, +2 authors, Stuart A Grossman.
Oncotarget, 2018 Jan 27; 8(69). PMID: 29371985    Free PMC article.
Highly Cited.
Radiation effects on antitumor immune responses: current perspectives and challenges.
Thomas Walle, Rafael Martinez Monge, +3 authors, Fernando Lecanda.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383033    Free PMC article.
Highly Cited. Review.
Diverse cutaneous adverse eruptions caused by anti-programmed cell death-1 (PD-1) and anti-programmed cell death ligand-1 (PD-L1) immunotherapies: clinical features and management.
John Shen, Jason Chang, +3 authors, Rajan P Kulkarni.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383039    Free PMC article.
Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8+ T cell trafficking.
David Taggart, Tereza Andreou, +7 authors, Mihaela Lorger.
Proc Natl Acad Sci U S A, 2018 Feb 02; 115(7). PMID: 29386395    Free PMC article.
Highly Cited.
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.
Marnix H Geukes Foppen, Elisa A Rozeman, +8 authors, John B A G Haanen.
ESMO Open, 2018 Feb 02; 3(1). PMID: 29387476    Free PMC article.
Highly Cited. Review.
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.
Isabella C Glitza, Michelle Rohlfs, +15 authors, Michael A Davies.
ESMO Open, 2018 Feb 02; 3(1). PMID: 29387478    Free PMC article.
The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma.
Anton Uryvaev, Maria Passhak, +2 authors, Gil Bar-Sela.
Med Oncol, 2018 Feb 02; 35(3). PMID: 29388007
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Christophoros Astaras, Rita de Micheli, +2 authors, Andreas F Hottinger.
Curr Neurol Neurosci Rep, 2018 Feb 03; 18(1). PMID: 29392441
PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations.
Lea Kristin Röver, Heidrun Gevensleben, +4 authors, Dimo Dietrich.
EBioMedicine, 2018 Feb 06; 28. PMID: 29396294    Free PMC article.
T cells specific for a TAP-independent self-peptide remain naïve in tumor-bearing mice and are fully exploitable for therapy.
Elien M Doorduijn, Marjolein Sluijter, +3 authors, Thorbald van Hall.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399388    Free PMC article.
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.
Anje Cauwels, Sandra Van Lint, +11 authors, Jan Tavernier.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399401    Free PMC article.
Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma.
Jeroen F Vermeulen, Wim Van Hecke, +8 authors, Niels Bovenschen.
Oncoimmunology, 2018 Feb 06; 7(3). PMID: 29399402    Free PMC article.
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Aurélie Durgeau, Yasemin Virk, Stéphanie Corgnac, Fathia Mami-Chouaib.
Front Immunol, 2018 Feb 07; 9. PMID: 29403496    Free PMC article.
Highly Cited. Review.
Emerging Biomarkers in Cutaneous Melanoma.
Anna Eisenstein, Estela Chen Gonzalez, +6 authors, Rhoda M Alani.
Mol Diagn Ther, 2018 Feb 08; 22(2). PMID: 29411301
A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer.
Zhixian Liu, Mengyuan Li, Zehang Jiang, Xiaosheng Wang.
Transl Oncol, 2018 Feb 08; 11(2). PMID: 29413765    Free PMC article.
Highly Cited.
A potential biomarker for anti-PD-1 immunotherapy.
Sangeeta Goswami, Sreyashi Basu, Padmanee Sharma.
Nat Med, 2018 Feb 08; 24(2). PMID: 29414936
Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer.
Manjima Dhar, Jessica Wong, +8 authors, Rajan P Kulkarni.
Sci Rep, 2018 Feb 09; 8(1). PMID: 29416054    Free PMC article.
Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.
Olivier Belzile, Xianming Huang, +4 authors, Bruce D Freimark.
Immunotargets Ther, 2018 Feb 09; 7. PMID: 29417044    Free PMC article.
Cancer Immunotherapy: Factors Important for the Evaluation of Safety in Nonclinical Studies.
Danuta J Herzyk, Helen G Haggerty.
AAPS J, 2018 Feb 09; 20(2). PMID: 29417397
Melanoma Brain Metastases: Local Therapies, Targeted Therapies, Immune Checkpoint Inhibitors and Their Combinations-Chances and Challenges.
Marvin Kuske, Ricarda Rauschenberg, +5 authors, Friedegund Meier.
Am J Clin Dermatol, 2018 Feb 09; 19(4). PMID: 29417399    Free PMC article.
Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells.
Qi Lai, Haiyong Wang, +7 authors, Zhenzong Du.
Oncogene, 2018 Feb 10; 37(17). PMID: 29422611
The anti-rheumatic drug, leflunomide, synergizes with MEK inhibition to suppress melanoma growth.
Kimberley Hanson, Stephen D Robinson, +4 authors, Grant N Wheeler.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423085    Free PMC article.
HLA class I loss and PD-L1 expression in lung cancer: impact on T-cell infiltration and immune escape.
Francisco Perea, Abel Sánchez-Palencia, +9 authors, Natalia Aptsiauri.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423109    Free PMC article.
Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Jenny H Lee, Georgina V Long, +8 authors, Matteo S Carlino.
JAMA Oncol, 2018 Feb 10; 4(5). PMID: 29423503    Free PMC article.
Highly Cited.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
G Redelman-Sidi, O Michielin, +4 authors, O Manuel.
Clin Microbiol Infect, 2018 Feb 11; 24 Suppl 2. PMID: 29427804    Free PMC article.
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Muhammad Zubair Afzal, Rodwell Mabaera, Keisuke Shirai.
J Immunother Cancer, 2018 Feb 13; 6(1). PMID: 29433557    Free PMC article.
Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.
Curtis J Perry, Andrés R Muñoz-Rojas, +11 authors, Susan M Kaech.
J Exp Med, 2018 Feb 14; 215(3). PMID: 29436395    Free PMC article.
Highly Cited.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.
Amanda J Oliver, Peter K H Lau, +4 authors, Clare Y Slaney.
Front Immunol, 2018 Feb 16; 9. PMID: 29445373    Free PMC article.
Temozolomide-associated hypermutation in gliomas.
Serah Choi, Yao Yu, +3 authors, Joseph F Costello.
Neuro Oncol, 2018 Feb 17; 20(10). PMID: 29452419    Free PMC article.
Highly Cited. Review.
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy.
Xin Hong, Ryan J Sullivan, +20 authors, Daniel A Haber.
Proc Natl Acad Sci U S A, 2018 Feb 18; 115(10). PMID: 29453278    Free PMC article.
Highly Cited.
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Michael Dougan, Jessica R Ingram, +12 authors, Stephanie K Dougan.
Cancer Immunol Res, 2018 Feb 21; 6(4). PMID: 29459478    Free PMC article.
Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer.
Megan Morisada, Michael Chamberlin, Clint Allen.
Head Neck, 2018 Feb 21; 40(6). PMID: 29461655    Free PMC article.
Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials.
Shiraj Sen, Kenneth Hess, +13 authors, Vivek Subbiah.
Br J Cancer, 2018 Feb 21; 118(6). PMID: 29462132    Free PMC article.
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Cutaneous Manifestations of Reactions to Biologics.
Iris M Otani, Amy S Levin, Aleena Banerji.
Curr Allergy Asthma Rep, 2018 Feb 22; 18(2). PMID: 29464437
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
Samuel Rosner, Erica Kwong, +9 authors, Michael A Postow.
Cancer Med, 2018 Feb 23; 7(3). PMID: 29468834    Free PMC article.
Highly Cited.
Recent advances in therapeutic strategies for unresectable or metastatic melanoma and real-world data in Japan.
Hisashi Uhara.
Int J Clin Oncol, 2018 Feb 23; 24(12). PMID: 29470725
Cardiotoxicity of Anticancer Therapeutics.
Jerry Dong, Hong Chen.
Front Cardiovasc Med, 2018 Feb 24; 5. PMID: 29473044    Free PMC article.
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Yared Hailemichael, Amber Woods, +17 authors, Willem W Overwijk.
J Clin Invest, 2018 Feb 27; 128(4). PMID: 29480817    Free PMC article.
Highly Cited.
ERK5 is activated by oncogenic BRAF and promotes melanoma growth.
Ignazia Tusa, Sinforosa Gagliardi, +8 authors, Elisabetta Rovida.
Oncogene, 2018 Feb 28; 37(19). PMID: 29483645    Free PMC article.
Systemic immune-inflammation index in germ-cell tumours.
Michal Chovanec, Zuzana Cierna, +11 authors, Jozef Mardiak.
Br J Cancer, 2018 Feb 28; 118(6). PMID: 29485980    Free PMC article.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +6 authors, Guillermo de Velasco.
Oncotarget, 2018 Mar 02; 9(9). PMID: 29492229    Free PMC article.
IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.
Erik Ladomersky, Lijie Zhai, +18 authors, Derek A Wainwright.
Clin Cancer Res, 2018 Mar 04; 24(11). PMID: 29500275    Free PMC article.
Highly Cited.
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Emily Z Keung, Esosa U Ukponmwan, Alexandria P Cogdill, Jennifer A Wargo.
Ann Surg Oncol, 2018 Mar 04; 25(7). PMID: 29500764    Free PMC article.
Melanoma Immunotherapy in the Elderly.
Marlana Orloff.
Curr Oncol Rep, 2018 Mar 04; 20(2). PMID: 29500787
Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future.
Alex B Blair, Adrian Murphy.
Curr Probl Cancer, 2018 Mar 05; 42(1). PMID: 29501212    Free PMC article.
Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.
Eleni Panagioti, Paul Klenerman, +2 authors, Ramon Arens.
Front Immunol, 2018 Mar 06; 9. PMID: 29503649    Free PMC article.
Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses.
Robert O Dillman, Andrew N Cornforth, +3 authors, Carol Depriest.
J Immunother Cancer, 2018 Mar 08; 6(1). PMID: 29510745    Free PMC article.
Combination immune checkpoint inhibitor therapy nivolumab and ipilimumab associated with multiple endocrinopathies.
Florence Gunawan, Elizabeth George, Adam Roberts.
Endocrinol Diabetes Metab Case Rep, 2018 Mar 08; 2018. PMID: 29511565    Free PMC article.
Incidence and Management of Immune-Related Adverse Events in Patients Undergoing Treatment with Immune Checkpoint Inhibitors.
Lisa A Kottschade.
Curr Oncol Rep, 2018 Mar 08; 20(3). PMID: 29511902
Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.
Mark A Samaan, Polychronis Pavlidis, +2 authors, Peter M Irving.
Nat Rev Gastroenterol Hepatol, 2018 Mar 08; 15(4). PMID: 29512649
Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod.
Taku Fujimura, Yumi Kambayashi, +6 authors, Setsuya Aiba.
Case Rep Oncol, 2018 Mar 09; 11(1). PMID: 29515401    Free PMC article.
Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.
Hiroki Nagai, Manabu Muto.
Int J Clin Oncol, 2018 Mar 09; 23(3). PMID: 29516216
Checks and Balances in Autoimmune Vasculitis.
Rebeca Hid Cadena, Wayel H Abdulahad, +4 authors, Elisabeth Brouwer.
Front Immunol, 2018 Mar 10; 9. PMID: 29520282    Free PMC article.
NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients.
Marta Schirripa, Wu Zhang, +18 authors, Heinz-Josef Lenz.
PLoS One, 2018 Mar 10; 13(3). PMID: 29522543    Free PMC article.
Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Hirokazu Sadahiro, Kyung-Don Kang, +25 authors, Ichiro Nakano.
Cancer Res, 2018 Mar 14; 78(11). PMID: 29531161    Free PMC article.
Highly Cited.
Putting the brakes on CTLA-4 inhibition in lung cancer?
Meghan J Mooradian, Justin F Gainor.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531902    Free PMC article.
Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.
Giuseppina Barutello, Valeria Rolih, +6 authors, Federica Riccardo.
Int J Mol Sci, 2018 Mar 15; 19(3). PMID: 29534457    Free PMC article.
Two cases of nonbacterial cystitis associated with nivolumab, the anti-programmed-death-receptor-1 inhibitor.
Kimihiro Shimatani, Tetsuro Yoshimoto, +3 authors, Akihiro Kanematsu.
Urol Case Rep, 2018 Mar 16; 17. PMID: 29541592    Free PMC article.
Efficacy of PD-1/PD-L1 inhibitors against pretreated advanced cancer: a systematic review and meta-analysis.
Hao Hu, Qian Zhu, +3 authors, Chang Ying Guo.
Oncotarget, 2018 Mar 17; 9(14). PMID: 29545941    Free PMC article.
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.
Jessica Da Gama Duarte, Sagun Parakh, +7 authors, Jonathan Cebon.
Front Immunol, 2018 Mar 20; 9. PMID: 29552014    Free PMC article.
Current status and perspectives in immunotherapy for metastatic melanoma.
Riccardo Marconcini, Francesco Spagnolo, +13 authors, Italian Melanoma Intergroup (IMI).
Oncotarget, 2018 Mar 20; 9(15). PMID: 29552325    Free PMC article.
NF1 mutations in conjunctival melanoma.
S L Scholz, I Cosgarea, +14 authors, K G Griewank.
Br J Cancer, 2018 Mar 22; 118(9). PMID: 29559732    Free PMC article.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, +30 authors, CheckMate 214 Investigators.
N Engl J Med, 2018 Mar 22; 378(14). PMID: 29562145    Free PMC article.
Highly Cited.
Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.
Gao Zhang, Lawrence W Wu, +41 authors, Jerry W Shay.
Clin Cancer Res, 2018 Mar 23; 24(19). PMID: 29563139    Free PMC article.
When worlds collide: Th17 and Treg cells in cancer and autoimmunity.
Hannah M Knochelmann, Connor J Dwyer, +4 authors, Chrystal M Paulos.
Cell Mol Immunol, 2018 Mar 23; 15(5). PMID: 29563615    Free PMC article.
Highly Cited. Review.
Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes.
E J Gibson, N Begum, +8 authors, M Lees.
Clinicoecon Outcomes Res, 2018 Mar 23; 10. PMID: 29563820    Free PMC article.
Exhaustion of the CD8+ T Cell Compartment in Patients with Mutations in Phosphoinositide 3-Kinase Delta.
Marjolein W J Wentink, Yvonne M Mueller, +5 authors, Peter D Katsikis.
Front Immunol, 2018 Mar 23; 9. PMID: 29563914    Free PMC article.
Updates on immunotherapy for colorectal cancer.
Aparna Kalyan, Sheetal Kircher, +2 authors, Al Benson.
J Gastrointest Oncol, 2018 Mar 23; 9(1). PMID: 29564182    Free PMC article.
Highly Cited. Review.
Aplastic anemia secondary to nivolumab and ipilimumab in a patient with metastatic melanoma: a case report.
D E Meyers, W F Hill, +3 authors, N A Nixon.
Exp Hematol Oncol, 2018 Mar 24; 7. PMID: 29568696    Free PMC article.
Melanoma and Immune Checkpoint Inhibitors.
Masutaka Furue, Takamichi Ito, +3 authors, Hiroshi Uchi.
Curr Oncol Rep, 2018 Mar 24; 20(3). PMID: 29569208
Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Frederick Arce Vargas, Andrew J S Furness, +32 authors, Sergio A Quezada.
Cancer Cell, 2018 Mar 27; 33(4). PMID: 29576375    Free PMC article.
Highly Cited.
Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Ming Yi, Shengnan Yu, +5 authors, Kongming Wu.
J Hematol Oncol, 2018 Mar 28; 11(1). PMID: 29580257    Free PMC article.
Highly Cited. Review.
Anti-CTLA-4 therapy requires an Fc domain for efficacy.
Jessica R Ingram, Olga S Blomberg, +15 authors, Michael Dougan.
Proc Natl Acad Sci U S A, 2018 Mar 28; 115(15). PMID: 29581255    Free PMC article.
Highly Cited.
Perspectives on the clinical development of immunotherapy in prostate cancer.
Lisa M Cordes, James L Gulley, Ravi A Madan.
Asian J Androl, 2018 Mar 28; 20(3). PMID: 29582792    Free PMC article.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Sandrine Niyongere, Andreas Saltos, Jhanelle E Gray.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593889    Free PMC article.
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.
Markus Eckstein, Ralph M Wirtz, +16 authors, Philipp Erben.
Oncotarget, 2018 Mar 31; 9(19). PMID: 29599921    Free PMC article.
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
Tomoko Kobayashi, Shintaro Iwama, +21 authors, Hiroshi Arima.
J Endocr Soc, 2018 Mar 31; 2(3). PMID: 29600292    Free PMC article.
Tumor lysate-based vaccines: on the road to immunotherapy for gallbladder cancer.
Daniel Rojas-Sepúlveda, Andrés Tittarelli, +9 authors, Flavio Salazar-Onfray.
Cancer Immunol Immunother, 2018 Mar 31; 67(12). PMID: 29600445    Free PMC article.
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.
Michael F Gowen, Keith M Giles, +11 authors, Iman Osman.
J Transl Med, 2018 Apr 03; 16(1). PMID: 29606147    Free PMC article.
Intensity-Modulated Radiotherapy Triggers Onset of Bullous Pemphigoid in a Patient with Advanced Melanoma Treated with Nivolumab.
Kayo Tanita, Taku Fujimura, +4 authors, Setsuya Aiba.
Case Rep Oncol, 2018 Apr 03; 11(1). PMID: 29606949    Free PMC article.
Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management.
Anna J Lomax, Jennifer Lim, +6 authors, Catriona McNeil.
J Skin Cancer, 2018 Apr 04; 2018. PMID: 29610684    Free PMC article.
Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
Minggui Pan, Mubarika Alavi, Lisa J Herrinton.
Perm J, 2018 Apr 05; 22. PMID: 29616914    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Unique Cytologic Features of Thyroiditis Caused by Immune Checkpoint Inhibitor Therapy for Malignant Melanoma.
Trevor E Angell, Le Min, Tad J Wieczorek, F Stephen Hodi.
Genes Dis, 2018 Apr 06; 5(1). PMID: 29619406    Free PMC article.
Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.
Denise L Crossland, Warren L Denning, +9 authors, John V Heymach.
Oncogene, 2018 Apr 07; 37(27). PMID: 29622795
Clinical assessment of immune-related adverse events.
Aaron Sosa, Esther Lopez Cadena, +2 authors, Rafael Rosell.
Ther Adv Med Oncol, 2018 Apr 07; 10. PMID: 29623110    Free PMC article.
New-onset insulin-dependent diabetes due to nivolumab.
Ali A Zaied, Halis K Akturk, Richard W Joseph, Augustine S Lee.
Endocrinol Diabetes Metab Case Rep, 2018 Apr 07; 2018. PMID: 29623210    Free PMC article.
CD8+ T Cells and NK Cells: Parallel and Complementary Soldiers of Immunotherapy.
Jillian Rosenberg, Jun Huang.
Curr Opin Chem Eng, 2018 Apr 07; 19. PMID: 29623254    Free PMC article.
Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice.
Ronald Anderson, Bernardo L Rapoport.
Front Oncol, 2018 Apr 07; 8. PMID: 29623257    Free PMC article.
Immune-related endocrine disorders in novel Immune checkpoint inhibition therapy.
Le Min.
Genes Dis, 2016 Dec 01; 3(4). PMID: 29623291    Free PMC article.
Immunotherapy of melanoma.
Iwona Lugowska, Pawel Teterycz, Piotr Rutkowski.
Contemp Oncol (Pozn), 2018 Apr 10; 22(1A). PMID: 29628796    Free PMC article.
A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.
Haidong Dong, Yiyi Yan, Roxana S Dronca, Svetomir N Markovic.
SOJ Immunol, 2017 Jan 01; 5(1). PMID: 29629436    Free PMC article.
Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials.
C Bryce Johnson, Shwe Y Win.
Oncoimmunology, 2018 Apr 11; 7(4). PMID: 29632719    Free PMC article.
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi, Taha Merghoub, Jedd D Wolchok.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634946    Free PMC article.
Highly Cited. Review.
Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade.
Sara Valpione, Sandro Pasquali, +4 authors, Vanna Chiarion-Sileni.
J Transl Med, 2018 Apr 13; 16(1). PMID: 29642948    Free PMC article.
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
Taku Fujimura, Yota Sato, +17 authors, Setsuya Aiba.
Oncotarget, 2018 Apr 13; 9(21). PMID: 29643991    Free PMC article.
Immunotherapy Plus Cryotherapy: Potential Augmented Abscopal Effect for Advanced Cancers.
Joe Abdo, David L Cornell, Sumeet K Mittal, Devendra K Agrawal.
Front Oncol, 2018 Apr 13; 8. PMID: 29644213    Free PMC article.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Aarti Asnani.
Curr Oncol Rep, 2018 Apr 13; 20(6). PMID: 29644505
Role of PD-1 during effector CD8 T cell differentiation.
Eunseon Ahn, Koichi Araki, +7 authors, Rafi Ahmed.
Proc Natl Acad Sci U S A, 2018 Apr 15; 115(18). PMID: 29654146    Free PMC article.
Highly Cited.
Radiotherapy and checkpoint inhibitors: a winning new combination?
Eric C Ko, Silvia C Formenti.
Ther Adv Med Oncol, 2018 Apr 18; 10. PMID: 29662550    Free PMC article.
Combination Cancer Immunotherapy in Hepatocellular Carcinoma.
Masatoshi Kudo.
Liver Cancer, 2018 Apr 18; 7(1). PMID: 29662830    Free PMC article.
Melanoma: What do all the mutations mean?
Elizabeth J Davis, Douglas B Johnson, Jeffrey A Sosman, Sunandana Chandra.
Cancer, 2018 Apr 18; 124(17). PMID: 29663336    Free PMC article.
Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report.
Go Noguchi, Sohgo Tsutsumi, +5 authors, Takeshi Kishida.
BMC Urol, 2018 Apr 20; 18(1). PMID: 29669553    Free PMC article.
Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
Ari Kassardjian, Peter I Shintaku, Neda A Moatamed.
PLoS One, 2018 Apr 20; 13(4). PMID: 29672601    Free PMC article.
Toxic epidermal necrolysis (TEN) associated with the use of nivolumab (PD-1 inhibitor) for lymphoma.
Liezel L Griffin, Laura Cove-Smith, +3 authors, Kim M Linton.
JAAD Case Rep, 2018 Apr 25; 4(3). PMID: 29687056    Free PMC article.
A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.
Yu Mi, Christof C Smith, +5 authors, Andrew Z Wang.
Adv Mater, 2018 Apr 25; 30(25). PMID: 29691900    Free PMC article.
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
Sander Bins, Edwin A Basak, +9 authors, Ron H J Mathijssen.
Br J Cancer, 2018 Apr 27; 118(10). PMID: 29695768    Free PMC article.
Bayesian adaptive clinical trials of combination treatments.
Kristian Thorlund, Shirin Golchi, Edward Mills.
Contemp Clin Trials Commun, 2018 Apr 27; 8. PMID: 29696213    Free PMC article.
Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
Elham Vosoughi, Jee Min Lee, +10 authors, Kevin B Kim.
BMC Cancer, 2018 Apr 29; 18(1). PMID: 29703161    Free PMC article.
Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barré Syndrome.
Alessio Cortellini, Alessandro Parisi, +5 authors, Corrado Ficorella.
Case Rep Oncol Med, 2018 May 01; 2018. PMID: 29707397    Free PMC article.
New Therapies in Head and Neck Cancer.
Rodell T Santuray, Daniel E Johnson, Jennifer R Grandis.
Trends Cancer, 2018 May 02; 4(5). PMID: 29709262    Free PMC article.
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Cesar August Santa-Maria, Taigo Kato, +14 authors, Francis J Giles.
Oncotarget, 2018 May 04; 9(27). PMID: 29721177    Free PMC article.
PD-L1 expression in medulloblastoma: an evaluation by subgroup.
Allison M Martin, Christopher J Nirschl, +19 authors, Michael Lim.
Oncotarget, 2018 May 04; 9(27). PMID: 29721192    Free PMC article.
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.
John Rieth, Subbaya Subramanian.
Int J Mol Sci, 2018 May 05; 19(5). PMID: 29724044    Free PMC article.
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden.
Carl Morrison, Sarabjot Pabla, +33 authors, Marc S Ernstoff.
J Immunother Cancer, 2018 May 11; 6(1). PMID: 29743104    Free PMC article.
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital.
Ria Winkelmann, Markus Schneider, +5 authors, Dirk Walter.
Int J Mol Sci, 2018 May 12; 19(5). PMID: 29747443    Free PMC article.
The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
Michele Guida, Stefania Tommasi, +12 authors, Giusepe Colucci.
BMC Cancer, 2018 May 12; 18(1). PMID: 29747595    Free PMC article.
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites.
Zachary S Morris, Emily I Guy, +15 authors, Paul M Sondel.
Cancer Immunol Res, 2018 May 12; 6(7). PMID: 29748391    Free PMC article.
Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors.
Zheng-Hang Wang, Lin Shen.
Chronic Dis Transl Med, 2018 May 15; 4(1). PMID: 29756118    Free PMC article.
CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.
Xian-Yang Li, Indrajit Das, +14 authors, Mark J Smyth.
J Clin Invest, 2018 May 15; 128(6). PMID: 29757192    Free PMC article.
A Convergence-Based Framework for Cancer Drug Resistance.
David J Konieczkowski, Cory M Johannessen, Levi A Garraway.
Cancer Cell, 2018 May 16; 33(5). PMID: 29763622    Free PMC article.
Highly Cited. Review.
Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations.
Ioannis Zerdes, Alexios Matikas, +2 authors, Theodoros Foukakis.
Oncogene, 2018 May 17; 37(34). PMID: 29765155    Free PMC article.
Highly Cited. Review.
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Young Kwang Chae, Ayush Arya, +4 authors, Francis Giles.
J Immunother Cancer, 2018 May 18; 6(1). PMID: 29769148    Free PMC article.
Highly Cited. Review.
Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment.
Nisha Subhash Patel, Anais Oury, +2 authors, Sandip Pravin Patel.
Oncologist, 2018 May 18; 23(10). PMID: 29769383    Free PMC article.
Adjuvant NY-ESO-1 vaccine immunotherapy in high-risk resected melanoma: a retrospective cohort analysis.
Michael Lattanzi, Joseph Han, +9 authors, Anna C Pavlick.
J Immunother Cancer, 2018 May 19; 6(1). PMID: 29773080    Free PMC article.
Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy.
Bo Zhu, Liming Tang, +15 authors, Peng Cao.
Oncogene, 2018 May 23; 37(36). PMID: 29786078
Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events.
Heinz Läubli, Catharina Balmelli, +10 authors, Sacha I Rothschild.
J Immunother Cancer, 2018 May 24; 6(1). PMID: 29789020    Free PMC article.
Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer.
Nicholas Borcherding, Ryan Kolb, +3 authors, Weizhou Zhang.
J Mol Biol, 2018 May 26; 430(14). PMID: 29800567    Free PMC article.
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.
Tae Kon Kim, Roy S Herbst, Lieping Chen.
Trends Immunol, 2018 May 29; 39(8). PMID: 29802087    Free PMC article.
Highly Cited. Review.
Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
Daniel da Motta Girardi, Tatiana Strava Correa, Marcela Crosara Teixeira, Gustavo Dos Santos Fernandes.
J Gastrointest Cancer, 2018 May 29; 49(3). PMID: 29806062
Persistent inflammation, immunosuppression, and catabolism and the development of chronic critical illness after surgery.
Philip A Efron, Alicia M Mohr, +8 authors, Scott C Brakenridge.
Surgery, 2018 May 29; 164(2). PMID: 29807651    Free PMC article.
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, +7 authors, Patrick J Stiff.
J Ovarian Res, 2018 May 31; 11(1). PMID: 29843813    Free PMC article.
Immunotherapy for Gastric Cancer: Time for a Personalized Approach?
Riccardo Dolcetti, Valli De Re, Vincenzo Canzonieri.
Int J Mol Sci, 2018 May 31; 19(6). PMID: 29844297    Free PMC article.
Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.
Winson S Ho, Herui Wang, +8 authors, Zhengping Zhuang.
Nat Commun, 2018 May 31; 9(1). PMID: 29844427    Free PMC article.
Cofilin-1 levels and intracellular localization are associated with melanoma prognosis in a cohort of patients.
Candelaria Bracalente, Adriana R Rinflerch, +5 authors, Hebe Durán.
Oncotarget, 2018 May 31; 9(35). PMID: 29844875    Free PMC article.
An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Ryan J Sullivan, Michael B Atkins, +25 authors, Howard L Kaufman.
J Immunother Cancer, 2018 Jun 01; 6(1). PMID: 29848375    Free PMC article.
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
Kerry Reynolds, Molly Thomas, Michael Dougan.
Oncologist, 2018 Jun 02; 23(9). PMID: 29853659    Free PMC article.
Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA.
Martin Zaleski, Makbule Kobilay, +7 authors, Stefan Holdenrieder.
Oncotarget, 2018 Jun 02; 9(32). PMID: 29854296    Free PMC article.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Hauke Stamm, Felix Klingler, +16 authors, Walter Fiedler.
Oncogene, 2018 Jun 02; 37(39). PMID: 29855615    Free PMC article.
Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens.
Mengjia Song, Xinfeng Chen, Liping Wang, Yi Zhang.
Chin J Cancer Res, 2018 Jun 05; 30(2). PMID: 29861603    Free PMC article.
Quantitative monitoring of circulating tumor DNA predicts response of cutaneous metastatic melanoma to anti-PD1 immunotherapy.
Guillaume Herbreteau, Audrey Vallée, +6 authors, Marc G Denis.
Oncotarget, 2018 Jun 05; 9(38). PMID: 29861869    Free PMC article.
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Rikke B Holmgaard, David A Schaer, +14 authors, Kyla E Driscoll.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866156    Free PMC article.
Highly Cited.
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination.
Jun Gong, Thang Q Le, +2 authors, Richard Tuli.
J Immunother Cancer, 2018 Jun 06; 6(1). PMID: 29866197    Free PMC article.
Emerging Trends in Clinical Research: With Implications for Population Health and Health Policy.
Benjamin Chin-Yee, S V Subramanian, +2 authors, Fahad Razak.
Milbank Q, 2018 Jun 06; 96(2). PMID: 29870114    Free PMC article.
RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer.
Elizabeth Ahern, Heidi Harjunpää, +4 authors, Mark J Smyth.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872559    Free PMC article.
Potential immune priming of the tumor microenvironment with FOLFOX chemotherapy in locally advanced rectal cancer.
Campbell S Roxburgh, Jinru Shia, +2 authors, Martin R Weiser.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872576    Free PMC article.
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2.
Na Luo, Luigi Formisano, +8 authors, Justin M Balko.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872580    Free PMC article.
Addressing the challenges of applying precision oncology.
Seung Ho Shin, Ann M Bode, Zigang Dong.
NPJ Precis Oncol, 2018 Jun 07; 1(1). PMID: 29872710    Free PMC article.
Cancer immunotherapy: broadening the scope of targetable tumours.
Jitske van den Bulk, Els Me Verdegaal, Noel Fcc de Miranda.
Open Biol, 2018 Jun 08; 8(6). PMID: 29875199    Free PMC article.
A mathematical modelling tool for unravelling the antibody-mediated effects on CTLA-4 interactions.
Aravindhan Ganesan, Theinmozhi Arulraj, Tahir Choulli, Khaled H Barakat.
BMC Med Inform Decis Mak, 2018 Jun 13; 18(1). PMID: 29890992    Free PMC article.
TGF-β in T Cell Biology: Implications for Cancer Immunotherapy.
Amina Dahmani, Jean-Sébastien Delisle.
Cancers (Basel), 2018 Jun 13; 10(6). PMID: 29891791    Free PMC article.
Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook.
Dharmesh Gopalakrishnan, Vadim S Koshkin, +2 authors, Petros Grivas.
Ther Clin Risk Manag, 2018 Jun 13; 14. PMID: 29892196    Free PMC article.
Rhabdomyolysis during high dose interleukin-2 treatment of metastatic melanoma after sequential immunotherapies: a case report.
Joseph I Clark, Shams Bufalino, Shruti Singh, Ewa Borys.
J Immunother Cancer, 2018 Jun 15; 6(1). PMID: 29898784    Free PMC article.
Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.
Alyona Weinstein, Ruth-Ann Gordon, +7 authors, Karla Lingard.
J Adv Pract Oncol, 2017 Jan 01; 8(1). PMID: 29900017    Free PMC article.
Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.
Osama Mohamad, Alberto Diaz de Leon, +17 authors, Raquibul Hannan.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900043    Free PMC article.
Optimized dendritic cell vaccination induces potent CD8 T cell responses and anti-tumor effects in transgenic mouse melanoma models.
Mareike Grees, Adi Sharbi-Yunger, +8 authors, Viktor Umansky.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900058    Free PMC article.
The possibility of cancer immune editing in gliomas. A critical review.
Víctor A Arrieta, Bernardo Cacho-Díaz, +3 authors, Adam M Sonabend.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900059    Free PMC article.
Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis.
Heidi Harjunpää, Stephen J Blake, +12 authors, Michele W L Teng.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900061    Free PMC article.
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma.
Joseph DiDomenico, Jonathan B Lamano, +7 authors, Orin Bloch.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900065    Free PMC article.
Blockade of LAG3 enhances responses of tumor-infiltrating T cells in mismatch repair-proficient liver metastases of colorectal cancer.
Guoying Zhou, Lisanne Noordam, +14 authors, Marco J Bruno.
Oncoimmunology, 2018 Jun 15; 7(7). PMID: 29900067    Free PMC article.
Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.
Maomao Zhang, Julie S Di Martino, +19 authors, Richard M White.
Cancer Discov, 2018 Jun 16; 8(8). PMID: 29903879    Free PMC article.
Highly Cited.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.